the signature - Mary Babb Randolph Cancer Center

Transcription

P.O. Box 9083
Morgantown, WV 26506-9083
THE
SIGNATURE
WVU Cancer Institute Annual Report
PUBLISHED SPRING 2016
2015
Contents
INTRODUCTION
NOTES
Accreditations 2
2
WVU Cancer Institute Locations 5
MAP
Welcome
Supporting Science and Soul 7
Increasing Access to Cancer Care in West Virginia
New Faces 7
The Gift of a Simple Meal
Radiation Oncology: Treatments and Technologies 8
Radiation Oncology Scores Big for Patients
CLINICAL CARE
West Virginia Cancer Registry Data 12
INFOGRAPHIC
10
Multidisciplinary Tumor Boards 13
Osborn Hematopoietic Malignancy and Transplantation Program 15
Patient Convenience, Comfort Emphasized Across Care Continuum
Lung Cancer Mortality Rates 17
INFOGRAPHIC
A Winning Team
CTRU at a Glance 19
A Second Chance at Life
MAP
Giving Options Back to Patients
Cancer Prevention and Control (CPC) Programs 22
Waging War on Lung Cancer
Continuing Education 23
CANCER PREVENTION AND CONTROL
Mobile Mammograms Performed Each Year 23
20
INFOGRAPHIC
Bonnie’s Bus 2016 Events 23
Colorectal Cancer Early Detection: CDC Grant to Improve the Odds
Academic Programs at the WVU Cancer Institute 28
10,000 and Counting
RESEARCH AND EDUCATION
Klinke Receives $1.7 Million Grant 29
24
Advancing Cancer Care with Research
From Russia to Morgantown: In Pursuit of Cancer Breakthroughs
Publications
OUR MISSION
OUR VISION
OUR VALUES
patients and their families while
Cancer Institute for the
teamwork, service, and
To provide excellent care to our
strengthening our research,
education, and service programs
to address the cancer health
disparities unique to the state of
West Virginia and Appalachia.
We will be a leading
people of West Virginia and
Appalachia.
We value quality, innovation,
accountability as the foundation
of our patient care, education,
and research programs.
WVU CANCER INSTITUTE CENTERS
MARY BABB RANDOLPH CANCER CENTER
#1 Cancer Hospital in West Virginia, U.S. News & World
Report
Accredited by the American College of Surgeons
Commission on Cancer
Accredited by the Foundation for the Accreditation of Cellular
Therapy for high quality medical and laboratory practice in
cellular therapies
Accredited by the National Accreditation Program for Breast
Centers
A Quality Oncology Practice Initiative Certified Practice:
Recognizing Excellence™
BETTY PUSKAR BREAST CARE CENTER
Accredited by the American College of Radiology
Federally certified by the FDA under the Mammography
Quality Standards Act to provide quality breast imaging
WVU CANCER INSTITUTE – UNIVERSITY HEALTHCARE
REGIONAL CANCER CENTER
Recipient of the Commission’s 2013 Outstanding
Achievement Award
CAMDEN CLARK REGIONAL CANCER CENTER
Welcome
to the Inaugural Issue of the
introduction
WVU Cancer Institute Signature
We hope this publication provides you with a glimpse into
the interworking of just a few of our several hundred faculty
and staff who have one mission: to provide the best in
cancer care, innovative research, and practical prevention
efforts to the citizens we serve.
INTRODUCTION
The name “Signature” was chosen intentionally to reflect
our commitment to unflagging excellence. Placing one’s
signature upon something conveys approval and takes
responsibility for the outcome. We have much to be proud
of, only a sliver of which will fit between these covers, but
we have selected a few items to which we are particularly
proud to sign our name.
You may have previously known us for more than 30 years
as the Mary Babb Randolph Cancer Center. While we still
retain that historically important name for our major clinical
site in Morgantown, we have recently rebranded WVU’s
overall organization of cancer work into the WVU Cancer
Institute. This name more accurately represents our identity
as a true academic medical center institute, active in clinical
care, research, education, and outreach. The name also
encompasses our expanded associated clinical services that
span the state of West Virginia and beyond, including our first
satellite clinic outside the state at Garrett Regional Medical
Center in Maryland. These services are complemented by
more than 60 cancer research laboratories and our Cancer
Prevention and Control offices on the Morgantown campus.
I hope you enjoy the following articles, which will provide a
sample of the latest stories involving hope, innovation, and
partnership at the WVU Cancer Institute.
Our best to you,
WVU CANCER INSTITUTE AT GARRETT REGIONAL
MEDICAL CENTER
FAIRMONT REGIONAL CANCER CENTER
William “Bill” Petros, PharmD, FCCP
Interim Director, WVU Cancer Institute
Volume I
2016
3
WVU CANCER INSTITUTE
THE SIGNATURE
introduction
Increasing Access to Cancer Care in
West Virginia
WVU CANCER INSTITUTE BROADENS NETWORK OF SERVICES
Breast cancer surgeon Hannah Hazard, MD, knows the health
“There’s a real need for a high level of cancer care here,”
significantly higher than the national average, many people
very grateful. I’m happy to come to work every day.”
challenges facing the people of West Virginia: cancer rates
living in rural areas with limited access to medical care, and
difficult travel conditions over rugged, mountainous terrain.
Dr. Hazard was born and raised in Morgantown and has
High-Quality Cancer Care Close to Home
spent most of her life here. As surgeon in chief and director
Collaboration began when centers approached WVU
at WVU to create a regional cancer network. Morgantown’s
their geographic areas. Since chemotherapy and radiation
of clinical services, she has worked tirelessly with a team
Mary Babb Randolph Cancer Center (MBRCC) is at the hub
of the newly formed WVU Cancer Institute.
As the WVU Cancer Institute’s flagship location, the MBRCC
the emphasis was on bringing those services closer to
where people live.
pancreatic, liver, and colorectal cancer surgery. The Center
days a week, six weeks in a row, one-and-a-half hours each
cancer knowledge and treatments. It promotes cancer
Close partnerships recently formed with regional medical
with specialists in Morgantown. Nurse navigators keep
WVUCancer.org
4 WVU Cancer Institute at Garrett
Regional Medical Center Oakland, MD
2 Fairmont Regional Cancer Center
—Newly opened in January 2016
—Infusion center for outpatient
chemotherapy treatments
Fairmont, WV
—Radiation oncology therapy
2
3
therapies at their own centers, maintaining close contact
patients informed and coordinate if they need surgery or
specialized treatment at the MBRCC.
PENNSYLVANIA
MARYLAND
4
5
1
VIRGINIA
OHIO
WEST VIRGINIA
5 WVU Cancer Institute – University
Healthcare Regional Cancer Center
way, over mountains and through snow storms.”
Instead, cancer specialists at the regional sites administer
care for the people of West Virginia and western Maryland.
—Inpatient care
needs radiation treatment for breast cancer to travel five
prevention and screening throughout the state.
centers provide a coordinated system of high-quality cancer
3 Mary Babb Randolph Cancer
Center and Betty Puskar Breast
Care Center Morgantown, WV
treatments often require multiple trips and/or multiple hours,
For example, Hazard explained, “It’s hard for a woman who
pursues both traditional research and clinical trials to improve
1 Camden Clark Regional
Cancer Center of WVU Cancer
Institute Parkersburg, WV
Medicine with a desire to enhance or expand cancer care in
offers a comprehensive breast cancer program and other
specialized services, such as stem cell transplants and
4
Hazard said. “The patient population is amazing, and they’re
Dr. Christopher Colenda, president and CEO of WVU Medicine – West Virginia University Health System; Dr. Hannah Hazard, director of clinical services and surgeon
in chief at WVU Cancer Institute; WVU President Gordon Gee; Dave McClure, president and CEO of WVU Medicine Camden Clark Medical Center; and Albert Wright,
president and CEO of WVU Medicine – WVU Hospitals and COO of WVU Medicine – West Virginia University Health System, pose at the October 2015 rebranding of
the Camden Clark Regional Cancer Center of WVU Cancer Institute.
Martinsburg, WV
KENTUCKY
—Inpatient care
Volume I
2016
5
NEW FACES
THE SIGNATURE
“We’re much stronger for being an institute. We all learn from
Hazard has already witnessed the positive impact of the
you’re sick.” She also noted how her father “felt a sense of
rather than free-standing, individual places,” Hazard affirmed.
of western Maryland. “We’ve seen patients benefit from
drug treatment.”
each other and provide better patient care as a collective unit
“There’s constant dialogue and a free flow of ideas between
us and our regional sites. Regional centers know their patient
populations, and we’re respectful of the resources they have
WVU Cancer Institute for West Virginians and residents
proximity of care. We’ve seen the successful navigation of
patients through our system from diagnosis and treatment
to survivorship services and support groups.
and their knowledge of the community.”
“The WVU Cancer Institute was designed with patient care
Satellite centers have the opportunity to participate in clinical
even stronger over time.”
trials of new medicines and procedures, plus screening and
and patient outcomes in mind. Its importance will become
prevention programs coordinated through the MBRCC.
being cared about. That he wasn’t just a patient receiving a
This sentiment is shared by Hannah Hazard, MD, surgeon
in chief and director of clinical services, who collaborated
with the family to implement the program. “It provides
reassurance to patients and family members of our
commitment to the complete care of each patient.”
Initial contributions from family and friends have supported
the program’s reach of 30 meals a day, five days a week.
Patients receiving lunches also have made contributions to
the fund, which Dr. Hazard hopes will grow to do even more.
The Gift of a Simple Meal
“I alone cannot change the world, but
I can cast a stone across the waters
to create many ripples.” ― Mother Teresa
A sandwich, a bowl of soup, a lively discussion of
Mountaineer basketball. Friendly chatter and lunchtime
SURGICAL ONCOLOGY
“Our intention is that Soup for the Soul should always and
Jon Cardinal, MD
Alan Thomay, MD
Jessica Partin, MD
Nezar Jrebi, MD
forever exist,” Hazard said, hoping that similar programs will
develop to serve patients at regional cancer centers.
This would be gratifying to Elswick, as well, since it would
further expand her father’s legacy of caring. “He was a man of
HEMATOLOGY/ONCOLOGY
great faith. He believed in feeding the hungry and giving water
to the thirsty. Literally, this is the program my father lived.
“We may not be able to cure every cancer, but we can
certainly take care of those who have it.”
sounds bounce around the room. The setting is not a cozy
bistro but the Infusion Center at the Mary Babb Randolph
Cancer Center. As they eat and socialize, the people in this
lunch crowd are receiving chemotherapy treatment.
Thanks to the Soup for the Soul program – begun by the
SCIENCE AND SOUL
of Pharmacy – patients benefit from a little extra care in the
ways our generous community can support patients
family of Ron Meredith, a 1967 graduate of the WVU School
The Soup for the Soul program is just one of the many
form of a comforting lunch. WVU student volunteers typically
and families battling cancer at the WVU Cancer
deliver the free lunches, along with a side of conversation.
Meredith’s family kicked off the program in October
2015 to pay forward the kindness and comfort Ron
experienced during his treatment at another center.
us build a culture of hope and wellness, offer new
life-saving treatments, and advance our leadership
nationally in the fight against cancer.
The WVU Cancer Institute offers many vehicles for
the motivation behind the program she, her mother, her
patients and their loved ones, from annual, capital
husband, and brother envisioned.
“I think sometimes we forget how meaningful doing small
things really is. A simple meal can really mean the world when
Nilay Shah, MD
Inderjit Mehmi, MD
Aaron Provenzano, DO
Gladys Onojobi, MD
(Garrett County)
Institute. Philanthropy, or love for humankind, helps
Betsy Elswick, PharmD, Meredith’s daughter and clinical
associate professor in the School of Pharmacy, described
Arnie Steele, of Moundsville, West Virginia, enjoys lunch at the Mary Babb
Randolph Cancer Center, thanks to the new Soup for the Soul Program.
Supporting
RADIATION ONCOLOGY
making a positive difference in the lives of cancer
campaign, and major gifts to memorials, planned
giving, and special events. To join our mission,
please visit wvucancer.org/give or contact our office
at 304-293-3711 or [email protected].
Malcolm Mattes, MD
6
WVUCancer.org
Ann Morris, MD
Todd Tenenholz, MD, PhD
THE SIGNATURE
introduction
Radiation Oncology Scores Big for
Patients
Imagine trying to hit a three-pointer while someone keeps
moving the basket. It’s a difficult shot even when the
defined target is stationary. But for some cancers, this is
complex diseases more successfully and with fewer side
effects for patients.”
exactly what happens. The simple act of breathing during
The new linear accelerators are equipped with on-board
area targeted for radiation.
new techniques like stereotactic body radiotherapy (SBRT).
radiation therapy can cause a tumor to move outside the
Patients receiving radiation treatment through the WVU
Cancer Institute can rest assured that specialists have
the most up-to-date tools for offsetting these types of
challenges. Equally important, they leverage leading-edge
technology to better visualize tumors, expertly pinpointing
cancers and sparing surrounding healthy tissue.
Advancements in radiation oncology at the Institute
accelerated in 2012 with the arrival of Geraldine Jacobson,
MD, MPH, MBA, chair of the Department of Radiation
Oncology. Her team resolved to modernize the outdated
facility and equipment.
radiation
beams),
greatly improving radiation treatment capabilities. In March
“Many of our patients in West Virginia come to us at a higher
high-quality manner.”
due to our multidisciplinary care and clinical trials,” she said.
oncologist a patient sees, he or she will be treated in a safe,
Benefits of recent radiation oncology advancements for
patients include:
More and better treatment options
Highly targeted treatment
Reduced side effects
Less damage to surrounding tissue
Shorter treatment times
Fewer treatments in some cases
Minimized patient discomfort
The Radiation Oncology Department’s state-of-the-art TrueBeam™ linear accelerator was added in March 2013.
and metastases to brain, is so precise that the results are
The progress in radiation oncology allows West Virginia
Teaming up for Expanded Access
its complications.
treatment to stay closer to home and still receive the most
The WVU Cancer Institute’s experience and expertise is
by accreditation from the American College of Radiology.
partnerships. In 2013, the Radiation Oncology Department
considered “surgical,” but without the risks of surgery and
residents who previously would have traveled out of state for
advanced level of care. That level of quality is demonstrated
treatment precision.
The increasingly robust Radiation Oncology Department
Broad Portfolio, Dominating Offense
Jacobson said, “Our full array of state-of-the-art equipment
with plans to add two more radiation oncologists in 2016.
Clinical trials expand treatment options even further through
has greatly enhanced our ability to manage advanced and
now includes five radiation oncologists and five physicists,
TREATMENTS AND TECHNOLOGIES
available through the Radiation Oncology Department of the WVU Cancer Institute
Image-Guided Radiation Therapy
High Dose Rate Brachytherapy
Gamma Knife™ Radiosurgery
Respiratory Gating
Intensity Modulated Radiation Therapy (IMRT)
Stereotactic Body Radiotherapy (SBRT)
WVUCancer.org
stage of cancer, yet we have better outcomes for those patients
precise treatments tailored to each patient’s anatomy.
Care on Par with the Best
features state-of-the art motion management for increased
8
for more standardized care. So no matter which radiation
2013, WVU added a TrueBeam™ linear accelerator, which
Hypofractionated Radiation
offers a broad portfolio of treatment to patients.
Specialists can now see tumors in real time, allowing for more
directly on the tumor. The procedure, used for brain tumors
installation of a new Trilogy linear accelerator (equipment
high-energy
workflow is a way of knowing we’re all working together
Knife, which precisely focuses multiple beams of radiation
A month after Dr. Jacobson’s arrival, the Department began
therapeutic
together again,” Jacobson noted. “Having a more organized
that having this assortment of technologies and clinical trials
imaging that enables image-guided radiation, making possible
In addition, the Department offers the state’s only Gamma
Game-Changer Upgrades
delivering
“We’ve kind of pulled it all apart and put our workflow back
Intraoperative Radiation Therapy (IORT)
Deep Inspiration Breath Hold
now available to other parts of the state through unique
added the Fairmont Regional Cancer Center, south of
Morgantown. They upgraded the facility and installed a new
linear accelerator so patients can receive care closer to
home and can see Institute doctors, who manage their care.
their innovative approaches for combating cancer. Jacobson
A collaboration with Camden Clark Regional Cancer Center
therapies that reduce radiation in some cases while spot
oncology services. While Camden Clark physicians manage
said breast cancer clinical trials are showing promise in
treating cancer in others through the use of SBRT. This spotspecific, high-intensity radiation is appropriate for cancers
that have spread to one or two locations. Lung cancers are
in Parkersburg offers physicist support for its radiation
their patients’ care, they have access to the Institute’s
multidisciplinary team of experts and clinical trials.
a prime example.
“We have been working very hard to make use of available
“The modern trend is to give patients the least possible
discuss patients with us remotely,” Jacobson explained.
treatment for the greatest possible gain,” Jacobson said. “Not
more, not less, but exactly what they need.” She explained
technology so that no matter where physicians are, they can
“Our goal is to provide better patient access within a
network of care. Ideally, this is where we’re going.”
Volume I
2016
9
Patient Convenience,
Comfort Emphasized
Across Care Continuum
They come to Morgantown from across the state and across state lines. They’re from
small cities and towns and often from rural areas. Facing a diagnosis of cancer, they are
worried and often afraid.
How will they find the right place to go and the right people to help them?
The team at the WVU Cancer Institute goes above and beyond to put people at ease,
while providing the highest possible level of cancer care.
“When people come to us, we understand it’s not just the diagnosis of cancer they face,”
said Deborah Falconi, RN, MSN, OCN, director of oncology services. “They’re facing
financial issues, lifestyle changes, emotional issues, and challenges with family dynamics.
“Some people don’t have a vehicle to get here; family members may need a place to stay
while a loved one receives treatment; or a patient who is post-surgery may need support
with everyday tasks at home. We help with all of these things.”
She noted that the continuum of care begins with cancer prevention and continues
through diagnosis, treatment, and living as a cancer survivor. Satellite medical centers
throughout the state and in Oakland, MD, allow people to receive consistently high-
CLINICAL CARE
quality cancer services in diverse locations.
“WE DO AS MUCH AS WE CAN to keep people close to their homes for services,”
Falconi said. “What the satellite centers can’t do, we’ll provide in Morgantown and stay in
close contact with regional doctors.”
Falconi and her team have worked tirelessly to integrate services from city to city and
hospital to outpatient clinic. Electronic medical records help make that happen, as
all health providers connected to a patient can read that patient’s up-to-the-minute
electronic chart at any time.
To make visiting the Morgantown campus less daunting, a nurse navigator and other
staff help patients smoothly transition from outpatient care to inpatient and back again.
A nurse navigator is assigned to each major cancer type so she (or he) can coordinate
testing, surgery, chemotherapy, radiation therapy, nutrition counseling, and a variety of
other services at the WVU Cancer Institute.
“It’s very unusual to have this seamless flow between inpatient and outpatient care,”
Falconi commented. “It’s safer, more efficient, and more patient centered. It ultimately
leads to a better quality of life for our patients.”
Last year, the WVU Cancer Institute logged more than 41,000 patient visits. “The bigger
we get, the harder we’re working to preserve our personal connection with the patient,”
Falconi said.
WVU Cancer Institute staff provide compassionate care to patients throughout their diagnosis and treatment.
Volume I
2016
11
MULTIDISCIPLINARY TUMOR BOARDS
WV CANCER REGISTRY DATA
The Mary Babb Randolph Cancer Center, flagship location for the WVU Cancer Institute, provided 41,333 patient visits in 2015, seeing
patients for close to 20 different cancer types. West Virginia Cancer Registry data from the previous four years illustrate the broad range of
cancer services provided by the WVU Cancer Institute. The Comprehensive Breast Cancer Program, accredited by the National Accreditation
Program for Breast Centers, sees more than 200 analytic (new) cases each year.*
a. BRAIN & OTHER NERVOUS SYSTEM
b. BREAST
c. DIGESTIVE SYSTEM
d. ENDOCRINE SYSTEM
e. FEMALE GENITAL SYSTEM
i. 26
f. LEUKEMIA
g. LYMPHOMA
h. MALE GENITAL SYSTEM
i. MYELOMA
j. ORAL CAVITY & PHARYNX
k. 174
g. 53
g. 58
f. 58
l. 34
2011
1,173
e. 75
d. 41
m. 117
n. 47
c. 130
h. 64
f. 63
1,236
d. 50
BONES & JOINTS 3
EYE & ORBIT 1
i. 22
KAPOSI SARCOMA 3
MESOTHELIOMA 2
c. 166
BONES & JOINTS 4
MESOTHELIOMA 2
i. 21
j. 81
k. 222
g. 68
1,279
l. 43
m. 83
n. 68
d. 57
n. MISCELLANEOUS
BONES & JOINTS 8
EYE & ORBIT 1
MESOTHELIOMA 1
SOFT TISSUE 17
h. 62
SOFT TISSUE 1
OTHER 31
*WV Cancer Registry data for 2015 were not available at time of publication.
BMT
Weekly, 8 am
Dr. Michael Craig
BRAIN
Weekly, 7 am
Dr. Javier Gonzalez
HEAD AND NECK
Weekly, 12 pm
Dr. Tanya Fancy
Dr. Mohammed Almubarak
GYNECOLOGICAL
ONCOLOGY
1st Thurs, 11 am
Dr. Mohammed Ashraf
MLS (BLOOD CANCERS)
1st, 3rd—5th Fri, 12 pm
Dr. Abraham Kanate
UROLOGY
2nd and 4th Wed, 4 pm
Dr. Tom Hogan
GASTROINTESTINAL
Weekly, 12 pm
Dr. Alan Thomay
TUESDAY
THORACIC
Weekly, 4 pm
Dr. Patrick Ma
CUTANEOUS
MALIGNANCIES
2nd Fri, 12 pm
Dr. Alan Thomay
A Winning Team
WVU EXPERTS POOL THEIR KNOWLEDGE FOR GREATER GOOD OF PATIENTS
Mary Smith* received a diagnosis of breast cancer at age 25,
dietitians, radiologists, psychiatrists, psychologists, plastic
the two-hour drive for her first appointment at the WVU
the discussion their unique knowledge and perspectives to
j. 68
providers discussed at length whether she should have
which treatment should be delivered first or if any clinical
of treatment. With these important details, her team of
m. 85
n. 55
c. 183
a. 66
BONES & JOINTS 6
EYE & ORBIT 4
healthcare team on the same day.
genetic
counselor,
fertility
specialist,
and
radiation
oncologist all on the same day. She might also learn that
she can receive radiation treatments near her home at one
Medical think tanks like the team that treated Smith are
“This is how we’ve always done clinical care,” said Hannah
Institute to discuss individual patients and their care. Each
“We’re all talking about the patient and making sure we’re on
called tumor boards. They meet regularly at the WVU Cancer
tumor board is a multidisciplinary team that is diseasespecific and addresses a different type of cancer: breast,
lung, colorectal, prostate, and half a dozen other types.
surgeons, medical oncologists, radiation oncologists,
SOFT TISSUE 15
OTHER 30
Morgantown and see a breast surgeon, plastic surgeon,
of WVU Cancer Institute’s regional cancer centers.
Team members perform a wide variety of roles, including
n. MISCELLANEOUS
trials are available to benefit the patient.
Advanced planning allows patients like Smith to visit
l. 56
1,289
caregivers and are valuable in determining answers about
once the cancer was eradicated. They carefully coordinated
*Name changed to protect patient privacy
2014
determine diagnoses and treatment plans for every patient.
The meetings promote clear communication among
her future visits, so she could see all key members from her
k. 191
surgeons, genetic counselors, and others. They bring to
who listened to her so they could understand her goals
what they could do to preserve her ability to have children
b. 251
OTHER 41
SARCOMA
1st and 3rd Wed, 7:30 am
Dr. Brock Lindsey
she met a team of physicians and healthcare professionals
a. 71
b. 254
BREAST
Weekly, 12 pm
Dr. Hannah Hazard
Dr. M. Salkeni
surgery or chemo first. Equally important, they discussed
f. 69
e. 57
FRIDAY
Cancer Institute Mary Babb Randolph Cancer Center, where
n. MISCELLANEOUS
SOFT TISSUE 11
OTHER 27
THURSDAY
just months before she planned to get married. She made
b. 233
2013
d. 57
n. 47
c. 155
a. 85
f. 61
e. 54
m. 123
a. 73
n. MISCELLANEOUS
g. 47
l. 40
2012
e. 67
WEDNESDAY
k. 186
b. 195
h. 50
j. 50
i. 20
j. 58
h. 87
k. RESPIRATORY SYSTEM
l. SKIN (Melanoma)
m. URINARY SYSTEM
n. MISCELLANEOUS
MONDAY
nurses, pharmacists, social workers, financial counselors,
Hazard, MD, surgeon in chief and director of clinical services.
the same page. This kind of care isn’t happening anywhere
else in the state.
“It’s the best model for patient care, and it’s a great forum
for the richest conversation about the right treatment for a
patient,” she added.
Volume I
2016
13
THE SIGNATURE
Clinical Care
A Second Chance at Life
STEM CELL TRANSPLANT PROGRAM OFFERS HOPE TO PATIENTS WITH BLOOD DISEASES
She contacted the WVU Cancer Institute, the state’s only
Renewed Appreciation for Life
The stem cell transplant team scheduled her immediately to
“The most gratifying part of my job is to offer hope to
stem cell transplant program and a strong research facility.
enroll in the clinical trial.
It was June 2009, and Becky Benson was making the
“My first chemotherapy treatment killed 95 percent of the
treatment of a severe headache. Her husband was working
“The doctors tried another treatment and another. They
trip from Bruceton Mills to Morgantown for emergency
out of town, so she drove herself, worrying about high blood
pressure or a possible stroke.
cancer cells, but they kept coming back,” Benson said.
used every chemotherapy treatment they had. In October,
my doctor said they couldn’t do anything else for me.”
Following blood tests and scans in the emergency room,
Benson’s oncologist suggested that she consider hospice
strongly believed that she had acute myelogenous leukemia
Cancer Institute. Her doctor cautioned that undergoing the
she received devastating news: the emergency doctor
(AML), an aggressive cancer of the blood and bone marrow.
care — unless she wanted to enter a clinical trial at the WVU
chemotherapy trial would be difficult and might diminish
The new chemotherapy did its work of killing Benson’s
cancer cells and making her ready for stem cell transplant.
On Dec. 8, 2009, donor stem cells arrived from Germany.
Michael Craig, MD, medical director of the program,
worked with his team to insert a central line below Benson’s
collarbone to infuse the cells into her bloodstream.
Once in her blood, Dr. Craig explained, “The stem cells
quickly find their way home to bone marrow space and begin
to regrow blood cells and rebuild the immune system.”
Performing at the Highest Level
“Stem cell transplant is a pretty standardized procedure,
and we meet all the national certification guidelines at the
WVU Cancer Institute,” Craig said.
“What I like about our program is that any type of stem
to come home.
cell transplant.
She had more tests the following day to confirm the
diagnosis and soon scheduled chemotherapy treatment.
“I’ll Fight This to the End”
“Everything was moving so fast I couldn’t keep up,” she
It took only the 30-minute drive home from Morgantown
commented.
Benson’s oncologist at a local hospital felt she would need
a stem cell transplant (commonly called a bone marrow
transplant) to beat the disease. But first, they needed to get
the cancer in remission.
14
her in remission, however, she would be eligible for a stem
WVUCancer.org
her transplant. She recently celebrated being cancer-free for
six years.
OSBORN HEMATOPOIETIC MALIGNANCY
AND TRANSPLANTATION PROGRAM
West Virginia’s only stem cell transplant program
for more than 20 years
About 60 patients a year, ages 16 to 75, receive stem cell
transplants through the WVU Cancer Institute.
The National Marrow Donor Program helps find matches
for WVU patients both nationally and internationally.
The program is accredited by the Foundation for the
Accreditation of Cellular Therapy.
myeloma, and other blood diseases.
we want West Virginians to have the opportunity for care as
close to home as possible.”
wondered if this was a dream.” She telephoned her husband
Benson followed up with Craig in the months and years after
self-donors, siblings, unrelated donors, or umbilical cords.
be separated from their families for weeks or months, and
her quality of life, with no guarantees for a cure. If it put
and can be difficult treatment, but there’s a hope for cure.”
The program offers every type of stem cell transplant
“People undergoing this procedure often have to travel and
Benson recalled, “My world stopped. The room went black. I
cured of their illness,” Craig noted. “It’s intensive treatment
cell transplant that can be performed in the world can be
performed at WVU for adult patients — with stem cells from
Becky Benson stitches a rag quilt to welcome her third grandson, who is due in August.
patients who may otherwise have very little chance to be
available to adults who have leukemia, lymphoma,
WVU Cancer Institute is the only facility in West Virginia to
offer photopheresis, a process that uses UV light to treat
white blood cells in stem cell transplant recipients
whose host cells are attacked by donor stem cells.
An entire WVU Cancer Institute team worked with Benson
every step of the way as she fought leukemia.
For every transplant patient, weekly meetings with
oncologists, nurses, pharmacists, social workers, and
others allow for multiple expert perspectives on diagnosis,
treatment, and support.
Benson has had some anxiety wondering why she survived,
and she still has some fear that the cancer will come back.
Her energy levels aren’t what they once were. But she’s
living and offering inspiration to her family, friends, and
acquaintances.
for Benson to make a decision. She vowed to her husband
Benson praised their work: “They’re amazing. They’re
“This is my new normal. I always counted my blessings,”
previous chemotherapy treatments surprisingly well and
friends with a lot of the nurses. This is truly one of the best
ages 3 and 4, are a particular joy.
and parents, “I’ll fight this to the end.” She had tolerated
was hopeful that the new clinical trial drug wouldn’t make
her “deathly sick.”
caring. Dr. Craig treats you like you’re his family, and I’m still
programs in the nation. Why would you go anywhere else?”
Benson said, “and now I do even more.” Her grandchildren,
“I look at life a whole lot different. I try to find the good in
everything. It’s a miracle that I’m here to wake up every day.”
Volume I
2016
15
THE SIGNATURE
Giving Options Back to Patients
FIRST IORT PROGRAM IN THE STATE SHAVES WEEKS OFF BREAST CANCER
TREATMENT TIME
Perplexing questions as to why some people get
making patient care better, improving access, and providing
to certain treatments while others do not — have
excellence in cancer care.”
For many women, the traditional three to six weeks of daily
whole-breast radiation treatments following a lumpectomy
are impossible. Women often juggle work schedules, child
care, and other family and community responsibilities. In
West Virginia, many women live an hour or more from a
people actually do end up saying, ‘I can’t do that; I’ll do the
IORT places control back in the hands of the patient, giving
back options that may have been taken away by geography
or logistics.
The WVU Cancer Institute is the first in the state to offer
for some patients.
Morgantown. Since the program launched in August, 18
IORT and is the only treatment center within two hours of
IORT offers additional benefits as well. The surrounding
breast, they insert the IORT applicator into the cavity where
less radiation exposure than with whole-breast radiation.
the lump had been, and radiation specialists apply radiation
therapy directly to the affected area. The patient receives
her surgery and her radiation therapy in one procedure,
Because only a small portion of the breast is irradiated, side
effects, such as redness and fibrosis, are reduced.
Not every breast cancer patient is a candidate for IORT.
“IORT makes cancer care more efficient. It may save patients
meet specific criteria in order for IORT to be an option. A
away from work,” Jessica Partin, MD, said. “Our patients
are challenged in that it’s a rural state. Twenty miles as the
crow flies is not really representative of what patients have to
WVUCancer.org
increasingly revealing clues for diagnosis, treatment,
and, potentially, cures.
considering the state has one of the highest incidence
concerning, West Virginia’s lung cancer mortality
rate is significantly higher than the national average,
according to 2012 cancer registry data from the
Centers for Disease Control and Prevention.
Lung cancer mortality per
100,000 people
60
59.6—3rd highest in
the nation
45
30
healthy tissue, including the heart and lungs, receive much
eliminating the need for additional visits.
a whole month or more of treatment, discomfort, and time
Program, lung cancers once shrouded in mystery are
women have received IORT.
lumpectomy for early-stage breast cancer patients. After
surgeons remove a cancerous lump from the patient’s
16
mastectomy instead.’”
Fortunately, intraoperative radiation therapy (IORT) at the
IORT is a new way of delivering radiation therapy after a
James Frederick Allen Comprehensive Lung Cancer
rates of lung cancer in the nation. Even more
said. “That might be a burden they can’t overcome. Some
WVU Cancer Institute can simplify breast cancer treatment
being conducted by faculty in the Sara Crile Allen and
altogether, raising their risk of recurrence by 30-40 percent.
for treatment for three weeks, let alone six weeks,” Partin
weeks of daily treatments are just the beginning of the list.
baffled scientists for decades. But thanks to research
This is good news for West Virginia residents,
“It can be very cumbersome for patients to travel every day
cancer diagnosis. Complicated procedures, surgery, and
cancer and some don’t — why some people respond
radiation center. For many of these women, their only options
are whole-breast removal or declining radiation therapy
Many worries jump to mind when a woman receives a breast
CLINICAL TRIALS EXPAND TO
IMPROVE OUTCOMES
travel and how hard it can be for someone to get to a cancer
center. Offering IORT demonstrates our commitment to
The IORT applicator irradiates the tumor bed directly, sparing healthy tissue.
Waging War on
Lung Cancer
Patients must be over age 50, and their cancer must
15
0
West
Virginia
National
Average
multidisciplinary team of cancer specialists consults over
each case to determine the best options for the individual
patient before any treatment begins.
Dr. Patrick Ma joined the WVU Cancer Institute in December 2014 to
lead the Lung Cancer Program in conducting clinical trials to advance
lung cancer cure rates.
Volume I
2016
17
THE SIGNATURE
New Physician Scientist Helps Lead the Way
sequencing — it’s all coming together in recent years to
The December 2014 arrival of Patrick C. Ma, MD, MS,
treatment in precision oncology.”
as co-leader of the Lung Cancer Program has intensified
Ma stated that recent advancements in targeted therapies
Dr. Ma came to WVU from the Cleveland Clinic Taussig
in West Virginia by further advancing cure rates, with some
Cancer Institute, where he was director of Aerodigestive
Oncology Translational Research.
and immunotherapy will help address lung cancer disparities
metastatic cancer patients surviving beyond three to five
years.
Clinical trials offer patients novel treatments that are not
Immunotherapy, which works to awaken a patient’s immune
the biological mechanisms and progression of cancer,
next five to 10 years, Ma predicted. “It’s only the dawn of
yet available through standard care. They shed light on
translating these discoveries into new therapies to treat
and prevent diseases. In many cases, they can improve a
patient’s length or quality of life, Ma noted.
Collaborating with program co-leader Yon Rojanasakul,
PhD, a professor of pharmaceutical sciences at the WVU
Cancer Institute, Ma has been the catalyst for building
system, will dominate the cancer therapeutics field in the
cancer immunotherapy. We are just witnessing the first
glimpse of the power of our anti-cancer capability in one’s
immune system, which can impact not only tumor response
but overall survival rate as well,” he said. “We’re taking
to patients at WVU. “Our current clinical trial portfolio in lung
immunotherapy with chemotherapy, taking the battle
cancer centers in the country,” he said.
“Clinical trial access offers our patients the most advanced
On the horizon is research that will help scientists use
cancer care.
cells throughout treatment and the molecular makeup of
personalized, patient-centered therapeutics for improved
of the human genome are accelerating the pace of cancer
research. “The genomics capability and next generation
WVUCancer.org
West Virginians and has received several
Commission on Cancer commendations
Morgantown, WV
for regularly exceeding the national
standard for percentage of patients
enrolled in clinical trials.
more personalized treatment.
control, and improvement. It also fosters best practices and
According to Ma, our information age and understanding
clinical trials in virtually all cancers common to
residual tumors (remaining after surgery or treatment) for
The Lung Cancer Program offers patients the most
More on the Horizon
> 25
of biomedical knowledge. The CTRU offers cancer
molecular profiling to better understand changes in tumor
and patient eligibility,” he explained. “This multidisciplinary
a sense of purpose and strength within our caregiver team.”
15-19
conduct clinical trials and expand the growing body
enable each drug to act in a stronger manner for a more
A medical oncologist, Ma stressed the importance of
teamwork is crucial to our excellence in clinical care, quality
services and expertise that investigators need to
than just chemotherapy and with less dangerous side effects.”
powerful punch.
cases and regularly review options for clinical trial studies
10-14
Morgantown, the unit is dedicated to providing the
immunotherapy attacks tumor cells in a less toxic manner
therapies.”
“We conduct discussion and review of our lung cancer patient
C. Byrd Health Sciences Center. Based in
to cancer cells more powerfully and proactively. “Novel
Drug combinations also are being designed strategically to
the WVU Cancer Institute’s multidisciplinary approach to
5-9
Cancer Institute, as well as at the WVU Robert
use combination immunotherapies as well as combining
cancer therapies, especially in the emerging area of cancer
immunotherapy and molecular genomics-guided precision
1-4 PATIENTS
Unit (CTRU) conducts clinical trials at the WVU
effectively reactivating them to attack the cancer cells.”
He also mentioned current leading-edge clinical trials that
cancer compares very well with other leading academic
The West Virginia University Clinical Trials Research
away the blindfold that tumor cells put on the immune cells,
momentum behind a multidisciplinary research team and
expanded the portfolio of lung cancer clinical trials available
18
pave the way for the arrival of a new era of personalized
the quality and quantity of clinical trials and translational
research for lung cancer within the WVU Cancer Institute.
CTRU AT A GLANCE
advanced cancer treatment and best possible access to
overall outcomes. “We’re optimistic about improving poor
lung cancer survival outcomes not just in West Virginia but
also nationwide,” Ma said.
He added, “It’s not unrealistic or unreasonable to start
talking about potential cures in previously incurable lung
cancers. We’re defying the odds one patient at a time.”
14% of trial participants
are out-of-state
Florida
Maryland
New York
Ohio
Pennsylvania
2014-2015
CANCER
PREVENTION
AND CONTROL
Colorectal Cancer Early
Detection: CDC Grant to
Improve the Odds
If you could increase your chances of winning the Mega Millions or Powerball lottery by 600
percent, wouldn’t you be curious to know how? What if you had the same odds to increase
your chances of surviving colorectal cancer?
The five-year survival rate for colorectal cancer increases by nearly 600 percent with early
diagnosis: from 13 percent at stage IV advanced-disease diagnosis to a 90 percent survival
rate for stage I early diagnosis.
The Cancer Prevention and Control (CPC) program of the WVU Cancer Institute seeks to
improve survival rates for West Virginians through a new initiative — West Virginia Program
to Increase Colorectal Cancer Screening (WVPICCS) — aimed at increasing the state’s
colorectal cancer screening rate to 80 percent or better. Funding for the initiative comes
from a five-year, $2.65 million grant awarded last summer by the Centers for Disease Control
and Prevention (CDC).
According to Mary Ellen Conn, WVPICCS project director, federal statistics show that West
Virginia’s colorectal cancer incidence and mortality rates are among the highest in the
country, while its overall screening rate is one of the lowest.
Conn explained the importance of screening: “Screening is our first line of defense. Its
purpose is early detection and identifying cancer before a person exhibits signs of disease.”
This is when the chance of treatment success and survival is much greater, she stated.
A Winning Ticket
Through the WVPICCS initiative, the WVU Cancer Institute targets primary care providers
and helps them take a leading role in improving screening rates.
“We’re focusing the effort on helping practices implement changes to increase their
screening rates and then sustaining them,” Conn said, referring to the work as a practicechange model.
“Any time you’re looking at creating change and sustaining change, the change needs to
occur in the entire system,” she noted. The WVPICCS team assists participating primary
care providers with tools and processes to identify and encourage appropriate patients to
be screened, following national guidelines for screening and surveillance.
The practice model includes evaluation, ongoing technical assistance, follow-up, professional
development training, and quality improvement. At its core is a customized plan for each
practice to improve its screening rate, featuring such tactics as strategically timed patient
reminders and follow-up.
“This goes beyond a report of what practices should do,” Conn explained. “We’re not only
The Strollin’ Colon was on display for community members, students, and employees at the WVU Health Sciences Center on
March 5, 2014. The 10-foot-by-12-foot inflatable colon shows both healthy and cancerous colon tissue.
talking to them about ideas but also working with them to do it. It’s really multifaceted.”
Volume I
2016
21
THE SIGNATURE
Conn’s team also provides training on how to tailor follow-
up and reminder calls to each patient and a way of tracking
these calls so no matter which staff person makes the calls,
educate providers and patients so they understand there’s
more than one type of screening that can be done.”
10,000 and
Counting
BONNIE’S BUS MAKES BREAST
CANCER SCREENINGS ACCESSIBLE
they can see previous contact attempts for each patient.
Flexible sigmoidoscopy is another option. It’s similar to
education, and motivation to each patient based on where
anesthesia, and is less expensive. However, it only views
The Bonnie Wells Wilson Mobile Mammography
five years, twice as often as colonoscopy for a person of
performed its 10,000th mammogram on September 19,
Conn said this helps staff better customize encouragement,
they are in their decision process.
In addition, the program includes targeted public education
and outreach through events, media, and patient education
colonoscopy but offers simpler bowel prep, does not require
the lower one-third of the colon and is recommended every
average risk.
and promotional materials.
Studies have shown that all three of these screening
During the first year, WVPICCS is partnering with 15
and morbidity.
Federally Qualified Health Centers, targeting providers
methods are effective in reducing colorectal cancer mortality
and clinics serving counties with high mortality rates of
“We stress to practices how research has shown that if you
these counties.
more likely to agree to screening,” Conn said.
colorectal cancer. Currently, 13 of the 15 providers serve
provide patients with a choice of screening options, they’re
Program — known familiarly as Bonnie’s Bus —
2015, in Martinsburg, WV.
Last year alone, the state’s only mobile mammography unit
“We’re more active with practices over the first two years,
helping them implement and sustain evidence-based
interventions tailored to the needs of the patients they serve,”
Conn reported. The WVPICCS team remains available to
practices over the five-year grant period to provide feedback
and assistance, helping ensure long-term success.
Conn plans to add eight more practices next year with a
goal of adding an average of 10 practices the remaining
years of the grant. This is the first time the CDC has awarded
this particular grant to organizations other than state health
With one year of the grant cycle nearly completed, the
program already is experiencing success through the
practice partnerships.
“We’re coming in and asking them to give us a lot of
information and looking at their process, putting them
under the microscope,” Conn noted. “They’ve really opened
7/6/16
Raleigh-Boone Medical Center
— Whitesville
MAMMOGRAMS PERFORMED EACH YEAR
7/7/16
Raleigh-Boone Medical Center
— Whitesville
7/8/16
Braxton Healthcare & Rehab Center
— Sutton
360
2009
commitment to quality care.”
departments. Only 32 programs in the country received the
grant, and WVU is one of only six university recipients.
Removing Barriers
Practice assistance from WVPICCS includes guidelines
on all three screening methods recommended by the US
Preventive Services Taskforce and not solely colonoscopy,
often considered the gold standard, since some patients
face barriers of fear, access, time, or cost.
For instance, practices might mail patients who’ve
traditionally avoided colonoscopies a free FIT (fecal
immunochemical test) kit, an annual test that looks for
hidden blood in the stool.
“The one big barrier we hear most often is the negative
perception of the bowel preparation,” Conn shared. “We
WVUCancer.org
787
1,529
2011
1,693
2012
CPC PROGRAMS
Appalachia Community Cancer Network
Bonnie Wells Wilson Mobile
Mammography Program
Mountains of Hope Cancer Coalition
WV Breast and Cervical Cancer
Screening Program
Public Education and Targeted Outreach
Professional Development
Partnership Coordination
WV Lung Cancer Project
WV Program to Increase Colorectal
Cancer Screening
7/16/16
Kingwood Fire Department — Kingwood
7/19/16
Community Care of WV (Clay Primary
Care) — Clay
7/20/16
Clendenin Health Center — Clendenin
7/21/16
Clendenin Health Center — Clendenin
7/27/16
Monroe Health Center — Union
7/28/16
Monroe Health Center — Peterstown
7/29/16
Bluestone Health Center — Princeton
1,995
2013
2,335
2014
themselves up to us. Their receptiveness and willingness
to work with us on this initiative really goes to show their
BONNIE’S BUS UPCOMING STOPS
provided mammograms to 2,167 women in West Virginia.
2010
22
CANCER PREVENTION AND CONTROL
2,167
2015
600
1,200
1,800
2,400
Since its launch in 2009, the Bus has traveled 107,692
miles to visit 43 of the state’s 55 counties. Nearly 12
percent of the mammograms performed by Bonnie’s
Bus each year are first-time mammograms. Most
importantly, 45 women have been able to seek treatment
for cancers discovered on the Bus.
“The number 10,000, that’s great; it means that we’re
reaching the women we want to reach. But the most
important thing is that we’re getting to the women of West
Virginia,” Sara Jane Gainor, director of Bonnie’s Bus, said.
“Now it’s time to start working toward 10,000 more.”
In the near future, that effort will be assisted by a new
bus equipped with updated technology, including 3D
mammography, with the goal of extending the same
state-of-the-art screening capabilities available at the
Betty Puskar Breast Care Center in Morgantown to
women anywhere in the state.
For additional dates and information, visit WVUCancer.org/bonnie.
CONTINUING EDUCATION
OPPORTUNITIES
WVU CANCER INSTITUTE ANNUAL BREAST
CANCER CONFERENCE: FROM MAMMOGRAMS
TO METASTATIC BREAST CANCER
July 15, 2016
WVU CANCER INSTITUTE ANNUAL FALL
CANCER CONFERENCE
October 7, 2016
WV WOMEN'S HEALTH CONFERENCE
Spring 2017
Volume I
2016
23
Advancing Cancer
Care with Research
Studying cancer cells in a cell culture dish in the laboratory yields
important, basic knowledge about the cells. Implant those same
human cancer cells into mice, and it exponentially expands the
understanding of how these cells behave in a living organism.
Tumor cells removed from actual patients and then immediately
transferred to mice — called patient-derived xenografts (PDX) —
have a much better chance to survive and grow than cells in a dish,
and importantly, retain the same characteristics as the initial tumor.
Scientists can then study and better understand the cancer cells’
function and growth and test various treatment strategies.
“We started working with PDX models a couple of years ago, with
the initial focus on breast cancer,” said Laura Gibson, PhD, deputy
director of the WVU Cancer Institute. “Over time, we will expand
to additional types of cancer that are particularly important to West
Virginia, such as lung cancer and head and neck cancer, as just
two examples.”
Dr. Gibson explained that PDX models are considered the gold
standard in any cancer research that strives to understand the
biology of a tumor and provide a rigorous testing ground for new
treatments.
“It is a strong pre-clinical tool that can provide essential information
for the development of new clinical trials for patients and novel
therapeutic strategies.”
RESEARCH AND
EDUCATION
Reducing the Burden of Cancer for West Virginians
The WVU Cancer Institute’s robust cancer research program
includes both “bench” (laboratory) and “bedside” (patient) studies.
In all of its research endeavors, the Institute never loses sight of its
ultimate priority: improving patient lives.
More than 60 research labs with 100 faculty members from eight
WVU schools and 33 departments are combining their expertise to
create a knowledge base that is greater than the sum of its parts.
WVU researchers also reach out to community partners and other
medical institutions, including those across the state.
“This team science approach is the only way to do research that
will really move us forward,” Gibson said. “Along with basic science
and clinical investigator teams, we engage across the campus to
include engineers, statisticians, and faculty and students from many
Dr. Elena Pugacheva (left) confers with PhD candidate Yuriy Loskutov (right). Pugacheva oversees a lab studying the molecular mechanisms
of invasion and metastasis, with a focus on developing new treatment strategies for metastatic breast cancer patients.
other disciplines to bring a unique perspective to the research.”
Volume I
2016
25
THE SIGNATURE
She continued, “The people of our state deserve top-quality
Gibson summed up the vision for WVU research efforts:
and caring physicians with access to information that is only
positively impact the prevention, diagnosis, and treatment
care, which is made possible by a combination of talented
generated by cutting-edge science. The lab-based work
informs both the standard of care in the clinic as well as the
development of novel clinical trials that our population can
have access to close to home. We are one team.”
“In collaboration with our clinical colleagues, we want to
of cancer. Our hope is to decrease the cancer burden across
the state, while contributing new knowledge to the scientific
community at the national and international levels. This goal
can only be met through strong partnerships.”
From Russia to Morgantown:
In Pursuit of Cancer Breakthroughs
Yuriy Loskutov has traveled halfway around the world to
Translational research promotes a smooth flow of knowledge
student in WVU’s Cancer Cell Biology Program (CCB), he is
Loskutov uses cancer tissue from patients to insert into
unravel the cellular mysteries of glioblastoma. A fourth-year
looking for ways to halt the spread of this deadly brain cancer.
Born in Siberia, Loskutov spent most of his youth in St.
Petersburg. He did his undergraduate and graduate work
in biology and physiology there. As a junior scientist at the
Pavlov Institute of Physiology in St. Petersburg, he learned
about a student exchange program seeking scientists to
mice; then he studies the cancer cells and tests treatments
that may alter how those cells function. One day, his findings
may spark new treatments for patients.
His specific research focus is the cancer cells’ cilia, the hairlike antennae that direct a cell’s function and reproduction.
work in US research labs.
“Multiple reports show cancer cells tend to have broken
Loskutov came to Morgantown in 2010. It didn’t take long
we could redirect cancer cells to a normal path or restrict
for him to decide that he wanted to stay at WVU. “I wanted
to delve deeper into cancer studies, so I applied to grad
school,” Loskutov said.
His wife, Maria, whom he met and married in Russia, came
cilia. We hypothesize that if we could restore proper cilia,
their growth,” he said.
Not Just Research for Its Own Sake
to WVU a few months after he arrived. She is also pursuing
His days aren’t spent just in the lab. He attended classes
lung cancer in another WVU lab.
reading current medical literature. Journal clubs, seminars,
her doctoral degree in Cancer Cell Biology and is studying
Graduate Students Power Research Efforts
“Our graduate students are our research engine,” said
Scott Weed, PhD, director of the Cancer Cell Biology
Graduate Program in the WVU School of Medicine. “They’re
responsible for conducting basic and translational science,
which will ultimately lead to the discovery of how cancer
works. It’s the first step to developing treatments and cures.”
26
from the lab to the bedside and back again. For example,
WVUCancer.org
in the first two years and spends a great deal of time
and student forums keep him in touch with other graduate
students, faculty, and clinicians.
“Our graduate students have opportunities to interact with
patient data, patient tissues, and the patients themselves,”
Dr. Weed said. “This contact enhances students’ awareness
and sense of urgency that we are doing this to help people,
not just doing research for its own sake.”
Yuriy Loskutov is training at WVU to research novel cancer cures.
Volume I
2016
27
Klinke Receives $1.7
Million Grant to Study
Immunotherapy
ACADEMIC PROGRAMS AT THE WVU CANCER INSTITUTE
CANCER CELL BIOLOGY GRADUATE PROGRAM
The WVU Cancer Cell Biology Graduate Program trains PhD and MD/PhD candidates to be cancer researchers. It provides
a strong foundation in cell biology, oncogenes and signaling networks, tumor microenvironment, bioinformatics, and
chemotherapeutics learned through course work and laboratory training.
HEMATOLOGY/ONCOLOGY FELLOWSHIP
WVU Hematology/Oncology fellows develop clinical expertise in cancer therapy, acquire knowledge of basic biology of neoplastic
The National Cancer Institute has awarded $1.7 million over
diseases, and carry out research on problems in Hematology/Oncology. Fellows see a variety of complex patients and work in
five years to WVU Cancer Institute researcher David Klinke,
inpatient, clinic, and research settings.
PhD, to conduct research into how immunotherapy can
strengthen the body’s immune system to improve treatment
ONCOLOGY PHARMACY RESIDENCY
for breast and lung cancers.
The WVU Oncology Pharmacy Residency provides experience in hematologic malignancy, solid tumor oncology, bone marrow
transplant, ambulatory oncology, investigational drug pharmacy, research, and palliative care.
Immunotherapies are poised to transform the therapeutic
RADIATION THERAPY PROGRAM
landscape for cancer, using the body’s own defenses to
combat disease, Dr. Klinke said. He will identify collateral
The Radiation Therapy Program at the WVU Cancer Institute is a 12-month certificate program for radiographers. Student therapists
targets for immunotherapy in breast and lung carcinomas and
obtain clinical experience in radiation treatment techniques, CT simulation, treatment planning, and brachytherapy implants.
broaden the clinical benefit available to patients.
UNDERGRADUATE SUMMER RESEARCH FELLOWSHIP PROGRAM
The Mary Babb Randolph Cancer Center offers undergraduate research fellowships in clinical and basic cancer research.
“What we’re trying to do is identify additional pathways that
The highly competitive 10-week fellowship program provides funding and opportunities for students who want to pursue
can augment these existing therapies, so that we may not
careers in cancer research.
have to release the brakes of the immune system too
much,” Klinke said. “There’s always a balance point.
We’re trying to identify how to do this so patients get a
In addition to international students like Yuriy and Maria,
Morgantown and Beyond
West Virginia, the Appalachian region, or nearby states.
When not studying or working in the labs at WVU,
their own people.
mountainous West Virginia terrain. They also enjoy snow
Weed said many of WVU’s graduate students come from
Most of these students feel a strong commitment to help
Loskutov feels that same desire to help. “The well-being
of cancer patients is very important. Glioblastoma is just
horrible; people usually live only a year, even with therapy. I
hope my research will help at least a little bit.”
A Passion for Science
The CCB program selects students who “have a passion for
skiing in the winter and bike riding on the trails along the
Monongahela River in spring, summer, and fall.
Loskutov noted that Morgantown’s climate is much warmer
than St. Petersburg’s. The Mountain State city is quite a bit
smaller than Russia’s second largest city, the population of
which houses nearly five million people. “Morgantown is
pretty quiet, but I like it,” he said.
He speculated that once he earns his PhD, he’ll pursue
Publications
In 2015, WVU Cancer Institute members published 138 cancer research articles, drawing together
multidisciplinary experts from medicine and pharmacy to chemistry and biomedical engineering.
BRAIN CANCER
A NOVEL PRECLINICAL METHOD TO QUANTITATIVELY EVALUATE
EARLY-STAGE METASTATIC EVENTS AT THE MURINE BLOOD-BRAIN
BARRIER. CANCER PREVENTION RESEARCH.
EXOSOME DELIVERED ANTICANCER DRUGS ACROSS THE BLOODBRAIN BARRIER FOR BRAIN CANCER THERAPY IN DANIO RERIO.
PHARMACEUTICAL RESEARCH.
Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP,
Lockman PR, Bai S.
research opportunities in the United States or Europe.
Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS,
the road.”
Weed’s hope for Loskutov and other Cancer Cell Biology
MOLECULAR DETERMINANTS OF BLOOD-BRAIN BARRIER
He continued, “Research is not instant gratification. It’s
discoveries at the post-doctoral level in top-tier institutions
Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR.
KAP1 PROMOTES PROLIFERATION AND METASTATIC PROGRESSION
RANDOMIZED PHASE II ADJUVANT FACTORIAL STUDY OF
Addison JB, Koontz C, Fugett JH, Creighton CJ, Chen D, Farrugia MK,
science,” said Weed. “They want to understand how cancer
works and find novel ways to help people with cancer down
searching, trying ideas, not being afraid to fail, and persevering
when you do fail.”
He described Loskutov as a “very insightful scientist. He
contributes to our journal clubs and seminar series. He asks
questions others don’t think of. He’s been wonderful.”
28
Loskutov and his wife like to hike and backpack across the
better clinical benefit, but reduce the side effects.”
WVUCancer.org
students is that they continue their work pursuing cancer
or industries. “We’re one link in a chain that’s ultimately
going to make people’s lives better. Our students do the preclinical work that ultimately translates into clinical benefit for
the patient.”
Jagannathan R, Lockman PR.
PERMEATION. THERAPEUTIC DELIVERY.
DOSE-DENSE TEMOZOLOMIDE ALONE AND IN COMBINATION
WITH ISOTRETINOIN, CELECOXIB, AND/OR THALIDOMIDE FOR
GLIOBLASTOMA. NEURO-ONCOLOGY.
Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De
Groot JF, Puduvalli VK, Colman H, Volas-Redd G, et al.
BREAST CANCER
OF BREAST CANCER CELLS. CANCER RESEARCH.
Padon RR, Voronkova MA, McLaughlin SL, Livengood RH, et al.
NKTR-102 EFFICACY VERSUS IRINOTECAN IN A MOUSE MODEL OF
BRAIN METASTASES OF BREAST CANCER. BIOMED CENTRAL CANCER.
Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK,
Eldon MA, Hoch U, Lockman PR.
Volume I
2016
29
THE SIGNATURE
COMPARISON BETWEEN ULTRASOUND AND PATHOLOGIC STATUS
PRO-METASTATIC NEDD9 REGULATES INDIVIDUAL CELL MIGRATION
THE IMPACT OF ACCESS TO CANCER CARE ON ADJUVANT
DIETARY COMPOUNDS GALANGIN AND MYRICETIN SUPPRESS
BREAST CANCER PATIENTS. AMERICAN SURGEON.
MOLECULAR CANCER RESEARCH.
APPALACHIA. VALUE IN HEALTH.
FOODS.
Tan X, Marshall V, Camacho F, Anderson RT, Balkrishnan R.
Huang H, Chen AY, Rojanasakul Y, Ye X, Rankin GO, Chen YC.
INHIBITION OF SHP2 IN BASAL-LIKE AND TRIPLE-NEGATIVE BREAST
MYRICETIN INHIBITS PROLIFERATION OF CISPLATIN-RESISTANT
DEPENDENCY, AND SENSITIVITY TO ANTI-HORMONE TREATMENT.
INTERNATIONAL JOURNAL OF ONCOLOGY.
OF AXILLARY LYMPH NODES IN CLINICALLY NODE-NEGATIVE
VIA CAVEOLIN-1-DEPENDENT TRAFFICKING OF INTEGRINS.
ENDOCRINE THERAPY USE AMONG BREAST CANCER SURVIVORS IN
Bailey A, Layne GP, Shahan C, Zhang J, Wen S, Radis S, Richmond B,
Kozyulina PY, Loskutov YV, Kozyreva VK, Rajulapati A, Ice RJ, Jones BC,
Partin JF, Hazard HW.
Pugacheva EN.
RADIATION EXPOSURE FROM DIAGNOSTIC PROCEDURES IN
KRUPPEL-LIKE FACTOR 4 SIGNALS THROUGH MICRORNA-206 TO
OF COMMUNITY AND SUPPORTIVE ONCOLOGY.
Lin CC, Sharma SB, Farrugia MK, McLaughlin SL, Ice RJ, Loskutov YV,
BIOMED CENTRAL CANCER.
Pugacheva EN, Brundage KM, Chen D, Ruppert JM.
Zhao H, Agazie YM.
PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER. THE JOURNAL
Chaudhary LN, Knapp S, Wen S, Xiao J, Marano GD, Kurian S, Layne GP,
Jacobson GM, Abraham J.
HIGH-FAT, HIGH-CALORIE DIET ENHANCES MAMMARY
CARCINOGENESIS AND LOCAL INFLAMMATION IN MMTV-PYMT
MOUSE MODEL OF BREAST CANCER. CANCERS (BASEL).
PROMOTE TUMOR INITIATION AND CELL SURVIVAL. ONCOGENESIS.
CELLS INDUCES BASAL-TO-LUMINAL TRANSITION, HORMONE
MESENCHYMAL CELL INVASION AND METASTASIS OF BREAST
CANCER. ONCOGENE.
COLORECTAL CANCER
A PHASE II, RANDOMIZED, DOUBLE BLIND TRIAL OF CALCIUM
Cowen S, McLaughlin SL, Hobbs GR, Coad JE, Martin KH, Olfert IM, Vona-
Loskutov YV, Kozyulina PY, Kozyreva VK, Ice RJ, Jones BC, Roston TJ,
Davis LC.
Smolkin MB, Ivanov AV, Wysolmerski RB, Pugacheva EN.
ALUMINOSILICATE CLAY VERSUS PLACEBO FOR THE PREVENTION
PREDICTING LATE-STAGE BREAST CANCER DIAGNOSIS AND
PRE-EXISTING DIABETES AND BREAST CANCER PROGNOSIS
CANCER TREATED WITH IRINOTECAN. SUPPORTIVE CARE IN CANCER.
RECEIPT OF ADJUVANT THERAPY: APPLYING CURRENT SPATIAL
ACCESS TO CARE METHODS IN APPALACHIA. MEDICAL CARE.
AMONG ELDERLY WOMEN. BRITISH JOURNAL OF CANCER.
Luo JH, Hendryx M, Virnig B, Wen S, Chlebowski RT, Chen C, Rohan T,
Donohoe J, Marshall V, Tan X, Camacho FT, Anderson R, Balkrishnan R.
Tinker L, Wactawski-Wende J, Lessin L, et al.
REGULATION OF ANTI-APOPTOTIC SIGNALING BY KRUPPEL-LIKE
BREAST CANCER SUBTYPE AS A PREDICTOR OF LYMPH NODE
CANCER. CELL DEATH AND DISEASE.
BREAST CANCER.
FACTORS 4 AND 5 MEDIATES LAPATINIB RESISTANCE IN BREAST
Farrugia MK, Sharma SB, Lin CC, McLaughlin SL, Vanderbilt DB, Ammer
AG, Salkeni MA, Stoilov P, Agazie YM, Creighton CJ, et al.
FEASIBILITY OF USING LOW-COST MOTION CAPTURE FOR
AUTOMATED SCREENING OF SHOULDER MOTION LIMITATION AFTER
BREAST CANCER SURGERY. PLOS ONE.
METASTASIS ACCORDING TO THE SEER REGISTRY. JOURNAL OF
Jacobson GM, Partin JF, Salkeni MA.
BREASTFEEDING: AN UNKNOWN FACTOR TO REDUCE HEART
DISEASE RISK AMONG BREASTFEEDING WOMEN. BREASTFEEDING
MEDICINE.
Kelly KM, Chopra I, Dolly B.
GENETIC COUNSELING CONTENT: HOW DOES IT IMPACT BEHAVIOR?
JOURNAL OF BEHAVIORAL MEDICINE.
Lamoshi AY, Salkini MW.
CHAETOGLOBOSIN K INDUCES APOPTOSIS AND G2 CELL CYCLE
ARREST THROUGH P53-DEPENDENT PATHWAY IN CISPLATINRESISTANT OVARIAN CANCER CELLS. CANCER LETTERS.
Li BY, Gao Y, Rankin GO, Rojanasakul Y, Cutler SJ, Tu Y, Chen YC.
GASTROINTESTINAL CANCER
EXTERNAL BEAM RADIATION THERAPY FOR SMALL CELL
CARCINOMA OF THE URINARY BLADDER. PRACTICAL RADIATION
ONCOLOGY.
THE INCIDENCE OF PELVIC AND PARA-AORTIC LYMPH NODE
A PROSPECTIVE STUDY. NEURO-ONCOLOGY.
EPITHELIAL CELL PROLIFERATION AND ANCHORAGE-INDEPENDENT
SIGNALING PATHWAY. FEMS MICROBIOLOGY LETTERS.
Zhu Y, Chen M, Gong Y, Liu Z, Li A, Kang D, Han F, Liu J, Liu J, Yuan Y.
Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy
Park J, Schlederer M, Schreiber M, Kim S, Ice RJ, Merkel O, Bilban M,
TRANSLATIONAL MEDICINE.
Glover K, Jones D, Wen S, et al.
OUTCOME. UROLOGY ANNALS.
GROWTH THROUGH ACTIVATION OF ERK-MEDIATED MITOGENIC
BRAIN METASTASES FROM METASTATIC BREAST CANCER PATIENTS:
CELL RESEARCH.
BIOPSY PATIENTS IN EARLY BREAST CANCER. ANNALS OF
Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M,
OFF-CLAMP ROBOTIC PARTIAL NEPHRECTOMY: TECHNIQUE AND
CAPECITABINE AND LAPATINIB UPTAKE IN SURGICALLY RESECTED
AF1Q IS A NOVEL TCF7 CO-FACTOR WHICH ACTIVATES CD44 AND
OPTIMAL MANAGEMENT OF SENTINEL LYMPH NODE POSITIVE
OF DIARRHEA IN PATIENTS WITH METASTATIC COLORECTAL
Kelly KM, Schoenberg NE, Wilson TD, Atkins E, Dickinson SL, Paskett ED.
Mattes MD, Kan CC, Dalbagni G, Zelefsky MJ, Kollmeier MA.
ROLE FOR CHONDROITIN SULFATE GLYCOSAMINOGLYCAN IN
van Kuppevelt TH, Mural RJ, Cutler ML, et al.
CERVICAL CANCER WORRY AND SCREENING AMONG APPALACHIAN
HELICOBACTER PYLORI FKBP-TYPE PPIASE PROMOTES GASTRIC
CG, Lockman PR, Simmons A, Weil RJ, Tabar V, et al.
Iida J, Dorchak J, Clancy R, Slavik J, Ellsworth R, Katagiri Y, Pugacheva EN,
Huang H, Chen AY, Ye X, Li BY, Rojanasakul Y, Rankin GO, Chen YC.
Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E.
Gritsenko V, Dailey E, Kyle N, Taylor M, Whittacre S, Swisher AK.
NEDD9-MEDIATED BREAST CANCER CELL GROWTH. EXPERIMENTAL
CANCER CELLS THROUGH A P53-DEPENDENT APOPTOTIC PATHWAY.
WOMEN. JOURNAL OF PRIMARY PREVENTION.
NEDD9/ARF6-DEPENDENT ENDOCYTIC TRAFFICKING OF MATRIX
METALLOPROTEINASE 14: A NOVEL MECHANISM FOR BLOCKING
OVARIAN CANCER CELL ANGIOGENESIS. JOURNAL OF FUNCTIONAL
PROMOTES BREAST CANCER METASTASIS. ONCOTARGET.
Hofbauer S, Addison JB, Zou J, et al.
ARRAYS OF SEGMENTED, TAPERED LIGHT GUIDES FOR USE WITH
LARGE, PLANAR SCINTILLATION DETECTORS. IEEE TRANSACTIONS
ON NUCLEAR SCIENCE.
GYNECOLOGIC & URINARY CANCER
PHASE I TRIAL OF SUNITINIB AND TEMSIROLIMUS IN METASTATIC
RENAL CELL CARCINOMA. CLINICAL GENITOURINARY CANCER.
Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen S, Siefker-Radtke AO,
Aparicio A, Corn PG, Tannir NM.
THE FLAVONOID NOBILETIN INHIBITS TUMOR GROWTH AND
ANGIOGENESIS OF OVARIAN CANCERS VIA THE AKT PATHWAY.
THE INTERACTIONS OF OBESITY, INFLAMMATION AND INSULIN
Chen J, Chen AY, Huang H, Ye X, Rollyson WD, Perry HE, Brown KC,
Rose DP, Gracheck PJ, Vona-Davis LC.
EXERCISE AND DIETARY ADVICE INTERVENTION FOR SURVIVORS
OF TRIPLE-NEGATIVE BREAST CANCER: EFFECTS ON BODY FAT,
PHYSICAL FUNCTION, QUALITY OF LIFE, AND ADIPOKINE PROFILE.
SUPPORTIVE CARE IN CANCER.
CARCINOMA ACCORDING TO THE SEER REGISTRY. JOURNAL OF
GYNECOLOGIC ONCOLOGY.
Mattes MD, Lee JC, Metzger DJ, Ashamalla H, Katsoulakis E.
Raylman RR, Vaigneur K, Stolin AV, Jaliparthi G.
RESISTANCE IN BREAST CANCER. CANCERS (BASEL).
METASTASIS IN UTERINE PAPILLARY SEROUS AND CLEAR CELL
INTERNATIONAL JOURNAL OF ONCOLOGY.
Rojanasakul Y, Rankin GO, Dasgupta P, et al.
IMAGE-GUIDED RADIOTHERAPY AND -BRACHYTHERAPY FOR
CERVICAL CANCER. FRONTIERS IN ONCOLOGY.
Dutta S, Nguyen NP, Vock J, Kerr C, Godinez J, Bose S, Jang S, Chi A,
Almeida F, Woods W, et al.
A COMPARATIVE STUDY OF OPEN, LAPAROSCOPIC AND ROBOTIC
PARTIAL NEPHRECTOMY IN OBESE PATIENTS. UROLOGY ANNALS.
Salkini MW.
HIGH-FREQUENCY ULTRASOUND IMAGING OF MOUSE CERVICAL
LYMPH NODES. JOURNAL OF VISUALIZED EXPERIMENTS.
Walk EL, McLaughlin SL, Weed SA.
HEAD & NECK CANCER
LYMPHATIC DRAINAGE PATTERNS IN ORAL SQUAMOUS CELL
CARCINOMA: FINDINGS OF THE ACOSOG Z0360 (ALLIANCE) STUDY.
OTOLARYNGOLOGY - HEAD AND NECK SURGERY.
Farmer RW, McCall L, Civantos FJ, Myers JN, Yarbrough WG, Murphy B,
O’Leary M, Zitsch R, Siegel BA.
DOWNREGULATION OF ATG14 BY EGR1-MIR152 SENSITIZES
INHIBITION OF AUTOPHAGY POTENTIATED THE ANTITUMOR EFFECT
INHIBITING CYTO-PROTECTIVE AUTOPHAGY. AUTOPHAGY.
CARCINOMA CELLS. PLOS ONE.
Kelly KM, Ellington L, Schoenberg NE, Jackson T, Dickinson S, Porter K,
Swisher AK, Abraham J, Bonner D, Gilleland D, Hobbs GR, Kurian S,
Leventhal H, Andrykowski MA.
Yanosik MA, Vona-Davis LC.
OVARIAN CANCER CELLS TO CISPLATIN-INDUCED APOPTOSIS BY
HEALTH BEHAVIORS AMONG BREAST CANCER PATIENTS AND
ADJUVANT THERAPY USE AMONG APPALACHIAN BREAST CANCER
He J, Yu JJ, Xu Q, Wang L, Zheng JZ, Liu LZ, Jiang BH.
Liu Z, Liu J, Li L, Nie D, Tao Q, Wu J, Fan J, Lin C, Zhao S, Ju D.
Kelly KM, Bhattacharya R, Dickinson SL, Hazard HW.
Tan X, Marshall VD, Anderson RT, Donohoe J, Camacho F, Balkrishnan R.
SELECTING BIOACTIVE PHENOLIC COMPOUNDS AS POTENTIAL
TUMOR AND STROMAL-BASED CONTRIBUTIONS TO HEAD AND
HUMAN OVARIAN CANCER CELLS. ONCOLOGY LETTERS.
Markwell SM, Weed SA.
SURVIVORS. CANCER NURSING.
SURVIVORS. MEDICINE (BALTIMORE).
AGENTS TO INHIBIT PROLIFERATION AND VEGF EXPRESSION IN
OF NEDAPLATIN IN CISPLATIN-RESISTANT NASOPHARYNGEAL
NECK SQUAMOUS CELL CARCINOMA INVASION. CANCERS (BASEL).
He Z, Li BY, Rankin GO, Rojanasakul Y, Chen YC.
30
WVUCancer.org
Volume I
2016
31
THE SIGNATURE
POSITRON EMISSION TOMOGRAPHY IN WARTHIN’S TUMOR
MIMICKING MALIGNANCY IMPACTS THE EVALUATION OF HEAD AND
NECK PATIENTS. AMERICAN JOURNAL OF OTOLARYNGOLOGY.
Rassekh CH, Cost JL, Hogg JP, Hurst MK, Marano GD, Ducatman BS.
INVESTIGATION OF A DEDICATED, HIGH RESOLUTION PET/CT
SCANNER FOR STAGING AND TREATMENT PLANNING OF HEAD AND
NECK CANCER. IEEE TRANSACTIONS ON NUCLEAR SCIENCE.
Raylman RR, Stolin AV, Sompalli P, Randall NB, Martone PF, Clinthorne NH.
ASSOCIATION OF PERIODONTITIS AND HUMAN PAPILLOMAVIRUS IN
ORAL RINSE SPECIMENS: RESULTS FROM THE NATIONAL HEALTH
AND NUTRITION SURVEY 2009-2012. JOURNAL OF THE AMERICAN
DENTAL ASSOCIATION.
Wiener RC, Sambamoorthi U, Jurevic RJ.
AGENTS AND CHEMOTHERAPY.
Cumpston AD, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig
M, Kanate AS.
MODELING THE BONE MARROW MICROENVIRONMENT’S INFLUENCE
ON LEUKEMIC DISEASE. TRANSLATIONAL BIOMEDICINE.
Evans R, Martin KH, Moses BS, Slone WL, Hare I, Piktel D, Thomas P, Gibson
LF.
MESENCHYMAL STROMAL CELLS DERIVED FROM ACUTE MYELOID
LEUKEMIA BONE MARROW EXHIBIT ABERRANT CYTOGENETICS AND
CYTOKINE ELABORATION. BLOOD CANCER JOURNAL.
Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR,
Becker PS.
ILEAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA
PRESENTING WITH SMALL BOWEL OBSTRUCTION: A CASE REPORT.
HEMATOLOGIC CANCER
A NOVEL METHOD TO ASSESS BONE MARROW PURITY IS USEFUL
IN DETERMINING BLAST PERCENTAGE BY FLOW CYTOMETRY IN
ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA. ANNALS OF
HEMATOLOGY & ONCOLOGY.
Aldawood AM, Kinkade Z, Rosado FG, Esan OA, Gibson LF, Vos JA.
IMPACT OF PRETRANSPLANTATION (18)F-FLUORODEOXY GLUCOSEPOSITRON EMISSION TOMOGRAPHY STATUS ON OUTCOMES
DIAGNOSTIC PATHOLOGY.
GUIDELINE-CONCORDANT LUNG CANCER CARE AND ASSOCIATED
NANOSCALE RESEARCH LETTERS.
STATES. JOURNAL OF GERIATRIC ONCOLOGY.
CHRONICALLY EXPOSED TO SINGLE-WALLED CARBON NANOTUBES.
Chen DQ, Stueckle T, Luanpitpong S, Rojanasakul Y, Lu YJ, Wang LY.
MRNA AND MIRNA REGULATORY NETWORKS REFLECTIVE OF MULTI-
POPULATION-BASED STUDY. CANCER EPIDEMIOLOGY.
Castranova V, Qian Y, Guo NL.
Nadpara PA, Madhavan SS, Tworek C.
SIMPSON’S PARADOX - AGGREGATING AND PARTITIONING
FEASIBILITY OF IMAGE-GUIDED RADIOTHERAPY AND CONCURRENT
STATISTICAL METHODS IN MEDICAL RESEARCH.
CANCER. CANCER INVESTIGATION.
POPULATIONS IN HEALTH DISPARITIES OF LUNG CANCER PATIENTS.
Fu P, Panneerselvam A, Clifford B, Dowlati A, Ma PC, Zeng G, Halmos B,
NITRIC OXIDE MEDIATES BLEOMYCIN-INDUCED ANGIOGENESIS
INHALATION EXPOSURE TO CARBON NANOTUBES (CNT) AND
CELLULAR BIOCHEMISTRY.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH PART B,
AND PULMONARY FIBROSIS VIA REGULATION OF VEGF. JOURNAL OF
VOSAROXIN PLUS CYTARABINE VERSUS PLACEBO PLUS
Iyer AK, Ramesh V, Castro CA, Kaushik V, Kulkarni YM, Wright CA,
CRITICAL REVIEWS.
Venkatadri R, Rojanasakul Y, Azad N.
Oberdorster G, Castranova V, Asgharian B, Sayre P.
CONTROLLED, DOUBLE-BLIND, MULTINATIONAL, PHASE 3 STUDY.
TUNGSTEN CARBIDE-COBALT NANOPARTICLES INDUCE REACTIVE
CARBON NANOTUBES INDUCE APOPTOSIS RESISTANCE OF HUMAN
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig M, Vey N, Strickland SA,
ANGIOGENESIS. BIOLOGICAL TRACE ELEMENT RESEARCH.
TOXICOLOGICAL SCIENCES.
CYTARABINE IN PATIENTS WITH FIRST RELAPSED OR REFRACTORY
ACUTE MYELOID LEUKAEMIA (VALOR): A RANDOMISED,
LANCET ONCOLOGY.
Schiller GJ, Jabbour E, Erba HP, et al.
FAILED AUTOLOGOUS TRANSPLANT FOR LYMPHOMA USING TLI
TRANSPLANT.
Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport
GG, Miklos DB, Benjamin JE, Johnston LJ, et al.
OXYGEN SPECIES, AKT, ERK, AP-1, NF-KAPPAB, VEGF, AND
Liu LZ, Ding M, Zheng JZ, Zhu Y, Fenderson BA, Li BY, Yu JJ, Jiang BH.
EFFECT OF BENDAMUSTINE IN COMBINATION WITH RITUXIMAB ON
Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen
AND EDERLY AML PATIENTS. CLINICAL LYMPHOMA, MYELOMA &
Lazarus HM.
Luanpitpong S, Li J, Manke A, Brundage KM, Ellis E, McLaughlin SL,
Angsutararux P, Chanthra N, Voronkova M, Chen YC, et al.
TRANSPLANT.
CANCER DISCOVERY.
AI, Cohen JB, Costa LJ, Dandoy C, et al.
HEMATOPOIETIC PROGENITOR CELL MOBILIZATION WITH “JUST-INTIME” PLERIXAFOR APPROACH IS A COST-EFFECTIVE ALTERNATIVE
TO ROUTINE PLERIXAFOR USE. CYTOTHERAPY.
Veltri L, Cumpston AD, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins
K, Craig M, Hamadani M, Kanate AS.
McGregor J, Muldoon L, Nesbit G, Peereboom D, et al.
LUNG CANCER
FORMULATION IN HEMATOLOGICAL MALIGNANCIES. ANTIMICROBIAL
Armstead AL, Minarchick VC, Porter DW, Nurkiewicz TR, Li BY.
MEDICAL JOURNAL.
IN VITRO: CONCORDANCE WITH IN VIVO STUDIES. TOXICOLOGY.
Snyder-Talkington BN, Dong C, Zhao X, Dymacek J, Porter DW, Wolfarth
MG, Castranova V, Qian Y, Guo NL.
VARIANT: NOVEL CANCER GENOMIC PREDICTIVE BIOMARKER.
NITRIC OXIDE INDUCES CANCER STEM CELL-LIKE PHENOTYPES IN
Ma PC.
CELL PHYSIOLOGY.
A PREDICTIVE MODEL FOR LYMPH NODE INVOLVEMENT WITH
MALIGNANCY ON PET/CT IN NON-SMALL-CELL LUNG CANCER.
JOURNAL OF THORACIC ONCOLOGY.
Mattes MD, Weber WA, Foster A, Moshchinsky AB, Ahsanuddin S, Zhang Z,
Shi W, Rizk NP, Wu AJ, Ashamalla H, et al.
RATIO OF LYMPH NODE TO PRIMARY TUMOR SUV ON PET/CT
ACCURATELY PREDICTS NODAL MALIGNANCY IN NON-SMALL-CELL
ACUTE INFLAMMATORY RESPONSES OF NANOPARTICLES IN AN
WVUCancer.org
PROMOTE CANCER STEM CELLS AND METASTASIS IN HUMAN LUNG
MET RECEPTOR JUXTAMEMBRANE EXON 14 ALTERNATIVE SPLICED
SUPERIOR SERUM CONCENTRATIONS WITH POSACONAZOLE
DELAYED-RELEASE TABLETS COMPARED TO SUSPENSION
Luanpitpong S, Chen M, Knuckles T, Wen S, Luo JH, Ellis E, Hendryx MS,
TRANSPLANTATION OUTCOMES IN CHILDREN, ADOLESCENTS
LEUKEMIA.
Cooper BW, Kindwall-Keller TL, Craig M, Creger RJ, Hamadani M, Tse WW,
Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins CE, Lockman PR,
TECHNOLOGY.
OPPORTUNITIES WITH BRAIN METASTASES. NEURO-ONCOLOGY.
MULTI-WALLED CARBON NANOTUBE-INDUCED GENE EXPRESSION
AND YOUNG ADULTS WITH HODGKIN LYMPHOMA. BONE MARROW
A PHASE I STUDY OF MIDOSTAURIN AND AZACITIDINE IN RELAPSED
PROMOTES TUMOR FORMATION”. ENVIRONMENTAL SCIENCE AND
CARCINOMA. ONCOGENE.
Rubenstein JN, Beatty C, Kinkade Z, Bryan C, Hogg JP, Gibson LF, Vos JA.
Bruce A, Evans R, Mezan R, Shi L, Moses BS, Martin KH, Gibson LF, Yang Y.
Munteanu MC, MacDonald DA.
UNSANCTIFYING THE SANCTUARY: CHALLENGES AND
EXPERIMENTAL PATHOLOGY.
A PROGNOSTIC MODEL PREDICTING AUTOLOGOUS
Burke JM, van der Jagt RH, Flinn IW, Craig M, Chen L, Morganroth J,
MINING PARTICULATE MATTER INDUCES NEOPLASTIC
Smolkin MB, Almubarak M, Perrotta PL.
THE BONE MARROW MICROENVIRONMENT FOR STUDY OF ACUTE
CHEMOTHERAPY AND PHARMACOLOGY.
Rojanasakul Y.
SLUG IS REQUIRED FOR SOX9 STABILIZATION AND FUNCTIONS TO
LYMPHOPROLIFERATIVE DISORDER. JOURNAL OF CLINICAL &
INDOLENT NON-HODGKIN OR MANTLE CELL LYMPHOMA. CANCER
Pongrakhananon V, Luanpitpong S, Stueckle TA, Wang LY, Nimmannit U,
LUNG: EVOLUTION FROM AN UNDERLYING REACTIVE
Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina
QT INTERVAL DURATION IN PATIENTS WITH ADVANCED DE NOVO
LUNG EPITHELIAL CELLS THROUGH FLICE-INHIBITORY PROTEIN.
TRENDS IN LUNG CANCER MOLECULAR TESTING. WEST VIRGINIA
EXTRANODAL MARGINAL ZONE LYMPHOMA OF THE
LYMPHOBLASTIC LEUKEMIA. PLOS ONE.
CARBON NANOFIBERS (CNF): METHODOLOGY AND DOSIMETRY.
Rojanasakul Y.
FACTORS ON OUTCOMES IN AIDS-RELATED NON-HODGKIN
THREE-DIMENSIONAL MICROFLUIDIC TRI-CULTURE MODEL OF
Nguyen NP, Kratz S, Chi A, Vock J, Vos P, Shen W, Vincent VH, Ewell L,
Kinkade Z, Esan OA, Rosado FG, Craig M, Vos JA.
TRANSFORMATION OF HUMAN BRONCHIAL EPITHELIAL CELLS AND
M, Tirelli U, Weiss R, et al.
CHEMOTHERAPY FOR LOCALLY ADVANCED NONSMALL CELL LUNG
Jang S, Altdorfer G, et al.
AND ANTI-THYMOCYTE GLOBULIN CONDITIONING. BONE MARROW
LYMPHOMA. ANNALS OF ONCOLOGY.
PROGNOSIS AMONG ELDERLY PATIENTS IN THE UNITED STATES: A
Leidner R.
TRANSPLANTATION.
CHANGES IN THE INFLUENCE OF LYMPHOMA- AND HIV-SPECIFIC
Almubarak M.
Dymacek J, Snyder-Talkington BN, Porter DW, Mercer RR, Wolfarth MG,
RESPONSE TO COMMENT ON “APPALACHIAN MOUNTAINTOP
Nishihori T, Agura E, Armand P, Jaglowski SM, et al.
Nadpara PA, Madhavan SS, Tworek C, Sambamoorthi U, Hendryx MS,
GUIDELINE-CONCORDANT TIMELY LUNG CANCER CARE AND
FIBROTIC PATHOLOGIES IN MICE. TOXICOLOGICAL SCIENCES.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AFTER
Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA,
HEALTH OUTCOMES AMONG ELDERLY PATIENTS IN THE UNITED
WALLED CARBON NANOTUBE-INDUCED LUNG INFLAMMATORY AND
AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
FOR NON-HODGKIN LYMPHOMA. BIOLOGY OF BLOOD AND MARROW
32
GENE EXPRESSION PROFILE OF HUMAN LUNG EPITHELIAL CELLS
HUMAN LUNG CANCER CELLS. AMERICAN JOURNAL OF PHYSIOLOGY
Yongsanguanchai N, Pongrakhananon V, Mutirangura A, Rojanasakul Y,
Chanvorachote P.
MICROFLUIDIC GRADIENT DEVICE FOR STUDYING MESOTHELIAL
CELL MIGRATION AND THE EFFECT OF CHRONIC CARBON
NANOTUBE EXPOSURE. JOURNAL OF MICROMECHANICS AND
MICROENGINEERING.
Zhang H, Lohcharoenkal W, Sun J, Li X, Wang L, Wu NQ, Rojanasakul Y, Liu Y.
LUNG CANCER. CLINICAL LUNG CANCER.
Mattes MD, Moshchinsky AB, Ahsanuddin S, Rizk NP, Foster A, Wu AJ,
Ashamalla H, Weber WA, Rimner A.
INTRA-TRACHEAL INSTILLATION RAT MODEL. PLOS ONE.
Volume I
2016
33
THE SIGNATURE
PROSTATE CANCER
PROSTATE-SPECIFIC ANTIGEN AND PERFLUOROALKYL ACIDS IN
THE C8 HEALTH STUDY POPULATION. JOURNAL OF OCCUPATIONAL
AND ENVIRONMENTAL MEDICINE.
Ducatman AM, Zhang J, Fan H.
MOLECULAR CHARACTERIZATION OF ENZALUTAMIDE-TREATED
BONE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.
EUROPEAN UROLOGY.
Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio
ELECTRON SPIN RELAXATION TIMES AND RAPID SCAN EPR
RESCUE OF DNA-PK SIGNALING AND T-CELL DIFFERENTIATION BY
ASSESSING THE IMPACT OF A TARGETED ELECTRONIC MEDICAL
MAGNETIC RESONANCE IN CHEMISTRY.
MODEL. PLOS GENETICS.
CANCER PATIENTS. THE JOURNAL OF COMMUNITY AND SUPPORTIVE
IMAGING OF PH-SENSITIVE AMINO-SUBSTITUTED TRITYL RADICALS.
Elajaili HB, Biller JR, Tseitlin MP, Dhimitruka I, Khramtsov VV, Eaton SS,
IMAGING DISULFIDE DINITROXIDES AT 250 MHZ TO MONITOR THIOL
EVALUATION OF AN SIPM-BASED PET/MRI INSERT. JOURNAL OF
Elajaili HB, Biller JR, Rosen GM, Kao JP, Tseytlin MP, Buchanan LA, Rinard
Raylman RR, Stolin A, Hou B, Ledden P.
AND PUBLIC HEALTH BY REGULATING ELECTRONIC CIGARETTE
MICRORNA-BASED THERAPEUTIC STRATEGIES FOR TARGETING
Blank MD, Eissenberg T.
REDOX STATUS. JOURNAL OF MAGNETIC RESONANCE.
GA, Quine RW, McPeak J, Shi Y, et al.
PRESENCE OF PSA AUTO-ANTIBODIES IN MEN WITH PROSTATE
PHARMACOLOGY.
PACEMAKER ACTIVITY. JOURNAL OF CARDIOVASCULAR
ABNORMALITIES (PROSTATE CANCER/BENIGN PROSTATIC
Huang J, Lin YC, Hileman SM, Martin KH, Hull RA, Yu HG.
Lokant MT, Naz RK.
ENHANCING THE DISCOVERY AND DEVELOPMENT OF
POTENTIAL APPLICATIONS OF IMAGE-GUIDED RADIOTHERAPY FOR
SYSTEMS PHARMACOLOGY: INTERLEUKIN-12 AS A CASE STUDY.
HIGH-RISK PROSTATE CANCER. FRONTIERS IN ONCOLOGY.
Nguyen NP, Davis R, Bose SR, Dutta S, Vinh-Hung V, Chi A, Godinez J,
Desai A, Woods W, Altdorfer G, et al.
IMPACT OF METFORMIN ON CLINICAL OUTCOMES AMONG MEN
IMMUNOTHERAPIES FOR CANCER USING QUANTITATIVE AND
Nguyen NP, Ries T, Vock J, Vos P, Chi A, Vinh-Hung V, Thompson S, Desai
A, Sroka T, Vo RA, et al.
BASIC CANCER RESEARCH
REDOX PROPERTIES OF THE NITRONYL NITROXIDE ANTIOXIDANTS
STUDIED VIA THEIR REACTIONS WITH NITROXYL AND
FERROCYANIDE. FREE RADICAL RESEARCH.
MEASURE FOR ADOLESCENTS SEEKING TO QUIT SMOKING.
CD8 (+) T CELL RESPONSE TO ADENOVIRUSVACCINATION AND
Branstetter SA, Mercincavage M, Dino GA, Horn KA.
SIMULATION AND ANALYSIS. BMC SYSTEMS BIOLOGY.
GENETIC RISKS TO NICOTINE DEPENDENCE PREDICT NEGATIVE
SUBSEQUENT SUPPRESSION OF TUMOR GROWTH: MODELING,
BIOPHYSICAL RESEARCH COMMUNICATIONS.
EVALUATION OF A MIDWIFE- AND NURSE-DELIVERED 5 A’S
FOR INVERSE PROBLEMS IN ENGINEERING BETTER MEDICINES.
CURRENT OPINION IN CHEMICAL ENGINEERING.
MOTIFS REGULATE BETA-CATENIN ACTIVITY IN THE ADHERENS
Klinke DJ, Horvath N, Cuppett V, Wu Y, Deng W, Kanj R.
CHLORIDE-HYDROGEN ANTIPORTERS CLC-3 AND CLC-5 DRIVE
OSTEOBLAST MINERALIZATION AND REGULATE FINE-STRUCTURE
BONE PATTERNING IN VITRO. PHYSIOLOGICAL REPORTS.
Woldman YY, Eubank TD, Mock AJ, Stevens NC, Varadharaj S, Turco J,
Gavrilin MA, Branchini BR, Khramtsov VV.
EXOSOMES: IMPROVED METHODS TO CHARACTERIZE THEIR
LOSS OF ADIPOCYTE VEGF IMPAIRS ENDURANCE EXERCISE
Cobb CO, Blank MD, Morlett A, Shihadeh A, Jaroudi E, Karaoghlanian N,
CAPACITY IN MICE. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE.
Zachwieja NJ, O’Connell GC, Stricker JC, Allen J, Vona-Davis LC, Bryner R,
Mandler W, Olfert IM.
ONCOLYTICS.
TYPE OF MULTIMORBIDITY AND COMPLEMENTARY AND
ORCHESTRATION OF ERBB3 SIGNALING THROUGH
ALTERNATIVE MEDICINE USE AMONG ADULTS. EVIDENCE-BASED
COMPLEMENTARY AND ALTERNATIVE MEDICINE.
Alwhaibi M, Bhattacharya R, Sambamoorthi U.
ORAL ANTINEOPLASTIC AGENTS: ASSESSING THE DELAY IN CARE.
CD44S-HYALURONAN INTERACTIONS PROTECT CELLS RESULTING
McCabe PM, Steinkamp MP, Halasz A, Chen Y, Yang S, Smith MS,
Anders B, Shillingburg A, Newton MD.
SOX9 INHIBITS BETA-TRCP-MEDIATED PROTEIN DEGRADATION TO
PROMOTE NUCLEAR GLI1 EXPRESSION AND CANCER STEM CELL
CELLULAR BIOLOGY.
Zahoransky-Kohalmi G, Swift M, Xu XP, Hanien D, et al.
DISRUPTIVE ENVIRONMENTAL CHEMICALS AND CELLULAR
MECHANISMS THAT CONFER RESISTANCE TO CELL DEATH.
CARCINOGENESIS.
PROPERTIES. JOURNAL OF CELL SCIENCE.
Narayanan KB, Ali M, Barclay BJ, Cheng Q, D’Abronzo L, Dornetshuber-
Deng W, Vanderbilt DB, Lin CC, Martin KH, Brundage KM, Ruppert JM.
Fleiss R, Ghosh PM, Gonzalez Guzman MJ, Luanpitpong S, Rojanasakul Y,
NEW CLASS OF 8-ARYL-7-DEAZAGUANINE CELL PERMEABLE
FLUORESCENT PROBES. BIOORGANIC AND MEDICINAL CHEMISTRY
et al.
SUBJECTIVE EFFECTS IN LOW- AND HIGH-FREQUENCY WATERPIPE
TOBACCO RESEARCH.
Kilgalen B, Austin J, Weaver MF, Eissenberg T.
CHRONIC DISEASE RISK SCREENING: CHARACTERISTICS OF
PARENTS WHO PARTICIPATE IN SCREENING WITH THEIR CHILDREN.
WEST VIRGINIA MEDICAL JOURNAL.
DIFFERENTIALLY TRIGGERS AN ANTITUMOR T CELL RESPONSE
Haworth KB, Arnold M, Gross AC, et al.
Chertok IR, Archer SH.
USERS: A DOUBLE-BLIND, PLACEBO-CONTROL STUDY. NICOTINE &
CANCER PREVENTION, CONTROL &
EDUCATION
Leddon JL, Chen CY, Currier MA, Wang PY, Jung FA, Denton NL, Cripe KM,
& WOMEN’S HEALTH.
Wu YT, Deng W, Klinke DJ.
Blair HC.
IN THE ABSENCE OF VIRUS PERMISSIVITY. MOLECULAR THERAPY
PRENATAL SMOKING CESSATION PROGRAM. JOURNAL OF MIDWIFERY
COMPARISON OF PUFF TOPOGRAPHY, TOXICANT EXPOSURE, AND
BIOMARKERS. ANALYST.
Larrouture QC, Nelson DJ, Robinson LJ, Liu L, Tourkova I, Schlesinger PH,
ONCOLYTIC HSV VIROTHERAPY IN MURINE SARCOMAS
REPORTS.
MORPHOLOGY, RNA CONTENT, AND SURFACE PROTEIN
HETEROINTERACTIONS AND HOMOINTERACTIONS. MOLECULAR AND
Cieply B, Koontz C, Frisch SM.
SUBSTANCE ABUSE.
IN SILICO MODEL-BASED INFERENCE: AN EMERGING APPROACH
LUCIFERIN-LUCIFERASE CHEMILUMINESCENCE. BIOCHEMICAL AND
Bobko AA, Khramtsov VV.
FROM EMT AGAINST ANOIKIS. MATRIX BIOLOGY.
DEVELOPMENT AND VALIDATION OF A SMOKING EXPECTANCIES
Sharma SB, Ruppert JM.
Chen X, Aggen SH, Chen J, Li L, Kendler KS, Blank MD, Eissenberg T.
JUNCTION PATHWAY. MOLECULAR AND CELLULAR BIOLOGY.
GERONTOLOGY INTERNATIONAL.
NICOTINE DELIVERY. ADDICTION.
DETECTION OF NITRIC OXIDE PRODUCTION IN CELL CULTURES BY
INTERLOCKED POSITIVE AND NEGATIVE FEEDBACK NETWORK
WITH NON-MELANOMA SKIN CANCER OF THE HEAD. GERIATRICS &
RESEARCH.
COMMENTARY ON BROSE, ET AL. (2015): PROTECTING INDIVIDUAL
Klinke DJ.
Raval AD, Thakker D, Vyas A, Salkini MW, Madhavan SS, Sambamoorthi U.
EFFECTIVENESS OF RADIOTHERAPY FOR ELDERLY PATIENTS
MUTANT AND WILD TYPE RAS IN CANCER. DRUG DEVELOPMENT
MD.
MOOD AND AFFECT IN CURRENT NON-SMOKERS. SCIENTIFIC
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
Klinke DJ, Birtwistle MR.
SKIN CANCER
NUCLEAR MEDICINE.
Bernens JN, Hartman K, Curley B, Wen S, Rogers JS, Abraham J, Newton
Wang Q, Klinke DJ, Wang Z.
WITH PROSTATE CANCER: A SYSTEMATIC REVIEW AND METAANALYSIS. PROSTATE CANCER AND PROSTATIC DISEASES.
ONCOLOGY.
H, Fisch P, Cantz T, Rudolph C, et al.
PP2 PREVENTS ISOPROTERENOL STIMULATION OF CARDIAC
RADIATION DOSE ESCALATION IN PATIENTS WITH EARLY STAGE
Rahman SH, Kuehle J, Reimann C, Mlambo T, Alzubi J, Maeder ML, Riedel
RECORD INTERVENTION ON THE USE OF GROWTH FACTOR IN
Eaton GR.
A, Troncoso P, Mohler J, et al.
HYPERPLASIA/PROSTATITIS). ANDROLOGIA.
TARGETED GENOME EDITING IN A PRKDC DEFICIENT IPSC DISEASE
CHEMOTHERAPY RESEARCH AND PRACTICE.
STUDY DESIGN, INTERVENTION, AND BASELINE CHARACTERISTICS
Cottrell LA, Lilly C, Murphy E, John C, Elliott E, Neal WA.
ASSESSING THE CARCINOGENIC POTENTIAL OF LOW-DOSE
EXPOSURES TO CHEMICAL MIXTURES IN THE ENVIRONMENT: THE
CHALLENGE AHEAD. CARCINOGENESIS.
Goodson WH, III, Lowe L, Carpenter DO, Gilbertson M, Manaf AA, Lopez de
Cerain SA, Lasfar A, Carnero A, Azqueta A, Amedei A, et al.
DOPAMINERGIC GENETIC VARIATION MODERATES THE EFFECT OF
NICOTINE ON CIGARETTE REWARD. PSYCHOPHARMACOLOGY (BERL).
Harrell PT, Lin HY, Park JY, Blank MD, Drobes DJ, Evans DE.
IMPROVING FAMILY HISTORY COLLECTION. JOURNAL OF HEALTH
COMMUNICATION.
OF A GROUP RANDOMIZED TRIAL INVOLVING A FAITH-BASED
Kelly KM, Shedlosky-Shoemaker R, Atkins E, Tworek C, Porter K.
BY FAITH) TO REDUCE WEIGHT AND CANCER RISK AMONG
PHARMACISTS’ PERCEPTIONS OF TOBACCO SALES IN AN
CLINICAL TRIALS.
Kelly KM, Agarwal P, Attarabeen O, Scott VG, Elswick BL, Dolly B, Tworek C.
HEALTHY EATING AND PHYSICAL ACTIVITY INTERVENTION (WALK
OVERWEIGHT AND OBESE APPALACHIAN ADULTS. CONTEMPORARY
ELEVATED-RISK POPULATION. JOURNAL OF PHARMACY TECHNOLOGY.
Baltic RD, Weier RC, Katz ML, Kennedy S, Lengerich EJ, Lesko SM, Reese
D, Roberto KA, Schoenberg NE, Young GS, et al.
LETTERS.
Dhimitruka I, Eubank TD, Gross AC, Khramtsov VV.
34
WVUCancer.org
Volume I
2016
35
WVu cAncEr InStItutE
tHE SIGnAturE
ATMOSPHERIC PARTICULATE MATTER IN PROXIMITY TO
MOUNTAINTOP COAL MINES: SOURCES AND POTENTIAL
ENVIRONMENTAL AND HUMAN HEALTH IMPACTS. ENVIRONMENTAL
GEOCHEMISTRY AND HEALTH.
Kurth L, Kolker A, Engle M, Geboy N, Hendryx MS, Orem W, McCawley MA,
EDITORIAL BOARD
William P. Petros PHARMD, FCCP
INTERIM DIRECTOR
304-293-0781
[email protected]
Crosby L, Tatu C, Varonka M, et al.
A NATIONWIDE MEDICAL STUDENT ASSESSMENT OF ONCOLOGY
EDUCATION. JOURNAL OF CANCER EDUCATION.
Mattes MD, Patel KR, Burt LM, Hirsch AE.
Hannah Hazard MD
DIRECTOR OF CLINICAL SERVICES
REFLECTIONS ON HOPE AND ITS IMPLICATIONS FOR END-OF-LIFE
CARE. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY.
Mattes MD, Sloane MA.
THE EVOLVING ROLE OF REGIONAL RADIATION ONCOLOGY
SOCIETIES IN RESIDENT EDUCATION. JOURNAL OF CANCER
Michael Craig MD
DIRECTOR OF THE BONE MARROW TRANSPLANT UNIT
Mattes MD.
EXPENDITURES AND OUT-OF-POCKET SPENDING BURDEN AMONG
ADULTS, MEDICAL EXPENDITURE PANEL SURVEY, 2009 AND 2011.
SUBSTANCE ABUSE.
EDITOR
Sarah Wisniewski
Deborah Falconi RN, MSN, OCN
DIRECTOR OF ONCOLOGY SERVICES
HEALTH CARE EXPENDITURES ASSOCIATED WITH DEPRESSION
AMY JOHNS
Director of Public Affairs and Creative Services
IN ADULTS WITH CANCER. THE JOURNAL OF COMMUNITY AND
Pan X, Sambamoorthi U.
EDUCATING PHYSICAL THERAPIST STUDENTS IN TOBACCO
Amy Bush BSN, MBA, RN, CNOR
VICE PRESIDENT OF OPERATIONS, WVU MEDICINE
OUTCOMES. JOURNAL OF PHYSICAL THERAPY EDUCATION.
Pignataro RM, Gurka MJ, Jones DL, Kershner RE, Ohtake PJ, Stauber W,
Swisher AK.
SURVEY OF U.S. HEMATOLOGY AND ONCOLOGY FELLOWS. JOURNAL
OF PALLIATIVE MEDICINE.
Thomas RA, Curley B, Wen S, Zhang J, Abraham J, Moss AH.
ESSENTIAL COMPONENTS OF CANCER EDUCATION. CANCER
RESEARCH.
Welch DR, Antalis TM, Burnstein K, Vona-Davis LC, Jensen RA, Nakshatri H,
Riegel AT, Spitz DR, Watson DK, Weiner GJ, et al.
LOCATIONS
Mary Babb Randolph Cancer Center
MORGANTOWN, WV
304-598-4500 OR 877-427-2894
Betty Puskar Breast Care Center
MORGANTOWN, WV
304-293-8012
WVU Cancer Institute – University Healthcare
Regional Cancer Center
MARTINSBURG, WV
304-267-1944
Camden Clark Regional Cancer Center
PARKERSBURG, WV
304-424-2256
WVU Cancer Institute at Garrett Regional
Medical Center
OAKLAND, MD
301-533-4222
Fairmont Regional Cancer Center
36
WVUCancer.org
ANGELA KNOPF
Manager of Media Relations
The Signature is published by WVU Medicine on behalf of
the WVU Cancer Institute.
CESSATION COUNSELING: FEASIBILITY AND PRELIMINARY
PALLIATIVE CARE TRAINING DURING FELLOWSHIP: A NATIONAL
DESIGNER
Katie Sickman
TONY CONDIA
Vice President of Marketing and Communications
Nasim A, Blank MD, Cobb CO, Eissenberg T.
SUPPORTIVE ONCOLOGY.
SOCIAL MEDIA
CHAIR OF RADIATION ONCOLOGY
Meraya AM, Raval AD, Sambamoorthi U.
OTHER TOBACCO PRODUCTS. JOURNAL OF CHILD & ADOLESCENT
DONOR INFORMATION
For information on supporting programs at the WVU Cancer
Institute, please contact:
Office of Philanthropy
304-293-3711
[email protected]
wvucancer.org/give
Geraldine Jacobson MD, MPH, MBA
PREVENTING CHRONIC DISEASE.
ADOLESCENT FORMER CIGARETTE SMOKERS’ VULNERABILITY TO
CLINICAL TRIALS
For information on current clinical trials at the WVU Cancer
Institute, contact the clinical trials team by e-mail at
[email protected] or visit
wvucancer.org/clinical-trials.
FACEBOOK facebook.com/WVUMedicine
TWITTER @WVUMedicine
INSTAGRAM @WVUMedicine
EDUCATION.
CHRONIC CONDITION COMBINATIONS AND HEALTH CARE
PATIENT INFORMATION
For information on patient services at the WVU Cancer
Institute, call our care team at 877-427-2894 or visit
wvucancer.org/patient-care.
FAIRMONT, WV
304-366-9999
All correspondence related to The Signature should be
addressed to:
WVU Medicine Marketing and Communications
P.O. Box 9083
Morgantown, WV 26506-9083
304-293-7087
[email protected]
Articles and photos may be reprinted with permission.
Visit the WVU Cancer Institute website at
wvucancer.org.
© 2016 WVU Medicine

the signature - Mary Babb Randolph Cancer Center

Transcription

Similar documents

102 things to do - Greater Morgantown CVB

102 Things To Do In Morgantown

2002 - Department of Physics

Foundation News - Summer 2014

Foreword - touchONCOLOGY

Big data Web sites: 40 billion indexed web pages Youtube: 100 hrs

Help along the way - Cayuga Medical Center

Perspective - West Virginia University

Marketplace of Homes Marketplace of Homes

10 Pearls: Radiation protection of staff in fluoroscopy

summer - Reed College of Media

experienced. focused. evolving. just like you.

An Invitation to all Breast Cancer Survivors

Taylor Extension News - WVU Extension Service

presTon counTy - Greater Morgantown CVB